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ABSTRACT
Psychotic disorders are characterized by symptoms that interfere with an
understanding  of  reality.  Such  symptoms consist  of,  for  example,  delusions
and hallucinations. Patients suffering from psychotic disorders, particularly
those with schizophrenia, often have cognitive deficits that compromise
efficient information processing. Patients with schizophrenia have been
found to have, in addition to a generalized cognitive deficit, deficits in
attention,  memory  and  executive  functioning,  which  are  related  to  the
impaired psychosocial functioning typically observed in these patients. In
addition to the patients themselves, non-psychotic relatives of schizophrenia
patients manifest similar, although milder, deficits in cognitive functioning,
suggesting that these cognitive features are related to a shared familial
vulnerability. Negative symptoms such as avolition, anhedonia and blunted
affect are often part of the clinical picture of schizophrenia. Anhedonia refers
to a diminished ability to experience pleasure and is often elevated in
patients with schizophrenia. It has been considered to be a vulnerability
factor for schizophrenia.
    People from the general population may also experience psychotic-like
thoughts or perceptions. These are similar to those of patients suffering from
psychotic disorders but milder, subclinical. Still, in adolescent and young
adult samples, psychotic-like symptoms have been found to be associated
with an elevated risk for future psychotic disorder.
    The aim of the present thesis was to study cognitive functioning and
clinical features in two middle-aged populations who presumably had a more
heightened susceptibility to psychotic disorders than the general population.
Samples were drawn from large population-based studies, a schizophrenia
family study and The Health 2000 and 2011 studies, from The National
Institute for Health and Welfare (previously National Public Health
Institute). The present study aimed to explore aspects of vulnerability to
psychotic disorders, first with healthy siblings of patients with schizophrenia,
and then with subjects with psychotic- or manic-like experiences from the
general population.
Healthy adult siblings from schizophrenia families had deficits in
neuropsychological tasks that had an executive and performance speed
component  in  comparison  with  population  controls.  The  level  of  social  and
physical anhedonia, as measured with the Chapman Scales, did not differ
between groups of siblings and population controls. Subjects with
schizophrenia spectrum disorders (schizophrenia, schizoaffective disorder or
schizophreniform disorder) had significantly poorer cognitive functioning
than their unaffected siblings and controls, and also had significantly higher
levels of social and physical anhedonia. Differences between middle-aged
8
subjects with psychotic-like or manic-like experiences and population
controls were rather small. Subjects with psychotic-like or manic-like
experiences had slightly lower reported level of functioning, and subjects
with manic-like experiences also had more depressive symptoms. However,
reported level of social and occupational functioning did not differ between
the groups. No major neuropsychological differences were found. Neither
psychotic-like nor manic-like experiences measured at baseline predicted
conversion to psychosis during an eleven-year follow-up. Still, subjects with
manic-like experiences had more non-psychotic psychiatric disorders, as well
as hospital treatment for those disorders, than population controls or
subjects with psychotic-like experiences at baseline.
    In conclusion, among middle-aged samples, healthy siblings from
families with schizophrenia have mild cognitive deficits, even in the absence
of a current non-psychotic psychiatric disorder. Elevated physical or social
anhedonia was not found in siblings, suggesting that elevated anhedonia is
more related to the illness than familial liability in middle-aged (above peak
risk age for conversion to psychosis) subjects with a familial risk for
psychosis.  Psychotic-like  experiences  in  middle-aged  subjects  may  be  more
benign regarding risk for future psychosis than in younger age groups, since
neither psychotic-like nor manic-like experiences at baseline predicted
psychosis during eleven-year follow-up. However, results should be




Psykoosisairauksissa oireet, jotka heikentävät todellisuudentajua ovat
tyypillisiä. Tällaisia oireita ovat mm. harhaluulot sekä harhanäyt.
Psykoosisairauksia sairastavilla potilailla, erityisesti skitsofreniapotilailla, on
usein kognitiivisia häiriöitä, jotka vaikeuttavat tehokasta tiedonkäsittelyä.
Skitsofreniapotilailla on havaittu laaja-alaisen kognitiivisen heikentymän
ohella vaikeuksia tarkkaavuudessa, muisti- ja toiminnanohjaustoiminnoissa.
Kognitiiviset häiriöt vaikuttavat osaltaan psykososiaalisen toimintakyvyn
heikentymiseen, joka on tyypillistä näillä potilailla. Myös
skitsofreniapotilaiden ei-psykoottisilla sukulaisilla on havaittu
samankaltaisia, joskin selvästi lievempiä, kognitiivisia vaikeuksia. Tällä
perusteella on ajateltu, että kognitiivisen toiminnan piirteet liittyisivät
perinnölliseen sairastumisalttiuteen. Negatiiviset oireet, kuten aloitekyvyn
puute, heikentynyt kyky kokea mielihyvää sekä tunneilmaisun niukkuus ovat
usein osa skitsofrenian kliinistä kuvaa. Anhedonia eli heikentynyt kyky
mielihyvän kokemiseen on usein tavanomaista voimakkaampaa
skitsofreniapotilailla kuin yleisväestössä. Sen on myös arvioitu liittyvän
alttiuteen sairastua skitsofreniaan.
    Myös yleisväestössä voi esiintyä psykoottisenkaltaisia ajatuksia tai
havaintoja. Nämä ovat samankaltaisia, mutta lievempiä, kuin
psykoosisairauden diagnoosin saaneilla henkilöillä. Kuitenkin nuoriso- ja
nuorten aikuisten aineistoissa psykoottisenkaltaisten oireiden on todettu
liittyvät kohonneeseen psykoosisairauden riskiin tulevaisuudessa.
    Tässä tutkimuksessa selvitettiin kognitiivista toimintakykyä sekä
psykososiaalisen toimintakyvyn piirteitä aikuisväestössä, kahdessa ryhmässä
joissa oletettavasti on kohonnut alttius psykoosisairauden puhkeamiseen
verrattuna yleisväestöön. Osajulkaisuissa kartoitettiin psykoosialttiuteen
liittyviä piirteitä sekä skitsofreniapotilaiden terveillä sisaruksilla, että
sellaisilla yleisväestön henkilöillä, jotka ovat raportoineet
psykoottisenkaltaisia tai maniankaltaisia oireita. Verrokkiryhmänä käytettiin
edustavaa otosta yleisväestöstä. Tutkimusaineistot ovat peräisin laajoista
väestöpohjaisista tutkimuksista jotka on toteutettu Terveyden ja
Hyvinvoinnin laitoksella (entinen Kansanterveyslaitos):
skitsofreniaperhetutkimuksesta sekä Terveys 2000 ja Terveys 2011 –
tutkimuksista.
    Skitsofreniapotilaiden terveillä aikuisilla sisaruksilla todettiin lieviä
puutoksia sujuvaa toiminnanohjausta ja nopeutta edellyttävissä
neuropsykologisissa tehtävissä verrattuna väestökontrolleihin. Chapmanin
anhedoniakyselyillä mitattu sosiaalisen ja fyysisen anhedonian määrä ei
eronnut sisarusryhmien ja kontrollien välillä. Skitsofreniaspektrin häiriötä,
eli skitsofreniaa, skitsoaffektiivista tai skitsofreniformista häiriötä,
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sairastavilla henkilöillä oli merkittävästi heikompi kognitiivinen
suoriutuminen verrattuna terveisiin sisaruksiinsa ja kontrolleihin. Heillä
todettiin myös enemmän sosiaalista ja fyysistä anhedoniaa. Psykoottisen –
tai maniankaltaisia oireita raportoineiden keski-ikäisten henkilöiden ja
kontrollien väliset erot olivat varsin pieniä. Oireita raportoineiden
henkilöiden psykososiaalinen toimintakyky oli hieman matalampi kuin
kontrollien ja maniankaltaisia oireita raportoineilla oli hieman enemmän
masennusoireita. Ammatillinen toimintakyky ei eronnut ryhmien kesken.
Lähtötilanteessa raportoidut psykoottisenkaltaiset tai maniankaltaiset oireet
eivät ennustaneet psykoosisairautta yhdentoista vuoden seurannassa.
Kuitenkin maniankaltaisia oireita raportoineilla henkilöillä oli seuranta-
aikana enemmän ei-psykoottista psykiatrista sairastavuutta sekä enemmän
sairaalahoitoja näihin kuin kontrolleilla tai psykoottisenkaltaisia oireita
raportoineilla henkilöillä.
    Johtopäätöksenä, skitsofreniapotilaiden terveillä sisaruksilla voi
esiintyä lieviä kognitiivisia vaikeuksia, vaikka heillä ei ole ajankohtaista ei-
psykoottista psykiatrista oireilua. Sisaruksilla ei esiintynyt sosiaalista tai
fyysistä anhedoniaa enemmän kuin kontrolleilla. Tämä voi viitata siihen, että
voimakas anhedonia liittyy enemmän skitsofreniaspektrin sairauteen kuin
perinnölliseen sairastumisalttiuteen keski-ikäisillä henkilöillä (yli
keskimääräisen psykoosiin sairastumisen riski-iän). Keski-ikäisten
psykoottisenkaltaiset oireet saattavat olla sairastumisriskin osalta
hyvänlaatuisempia kuin nuoremmissa ikäryhmissä. Suhteellisen pienet
ryhmäkoot huomioiden erityisesti sairastumisriskiä tulisi kuitenkin arvioida
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1 INTRODUCTION
Psychotic disorders are severe mental disorders with delusions,
hallucinations and severe behavioural abnormalities that lead to a loss of
contact with reality (APA, 2013). Scizophrenia is the most common psychotic
disorder and is also considered to be the most severe, but psychotic
symptoms are not specific to schizophrenia (APA, 2013). Symptoms in
psychotic disorders can be clustered into categories which consist of:
psychosis, which is also called the positive symptom dimension, alterations
in drive and volition, alterations in neurocognition, such as difficulties in
memory, attention and executive functioning and affective dysregulation
(Van Os and Kapur, 2009). In schizophrenia, the onset is typically at a young
age  with  subtle  cognitive,  motor  and  social  dysfunction  emerging  first  in
varying, unspecific ways, progressively worsening into more severe
prodromal symptoms and leading gradually to the onset of first psychotic
episode (Bora et al. 2014; Addington et al. 2016). Currently, it is thought that
psychosis proneness (vulnerability to psychosis) is a continuum with
individual differences existing in a person’s vulnerability to developing a
psychotic disorder (Ingram et al. 2005; Janssen et al. 2016). Vulnerability
may be due to a combined effect of personal genetic background and certain
environmental stressors, and only the most susceptible would cross over the
disease threshold (Binbay et al. 2012; Ortega-Alonso et al. 2017). Genetic
factors play a significant role in the development of psychotic disorders
(Ripke et al. 2013; Cardno and Owen, 2014). Familial vulnerability is a
known  risk  factor  for  future  psychosis  based  on  studies  on  offspring  or
relatives of subjects with schizophrenia or bipolar disorder (Liu et al. 2015).
Severe, acute forms of psychotic symptoms characterize disorders such as
schizophrenia and psychotic bipolar disorder, but subclinical psychotic-like
experiences are also present in the general population (van Os et al. 2009).
These psychotic-like experiences can consist of odd behaviour, social
withdrawal, anxiety, lack of feeling, magical ideation or perceptual
abnormalities that are milder than in psychotic disorders (Van Os et al.
2009).
    From previous studies it is known that non-psychotic family members
of schizophrenia patients have mild cognitive deficits that manifest in
neuropsychological tests (Tuulio-Henriksson et al. 2002). Also, among young
age groups, subjects with psychotic-like experiences have often been found to
have cognitive deficits which together with psychotic-like experiences have
been found to predict future psychosis, at least in clinical high-risk
populations (Seidman et al. 2006). The present thesis explored two adult
populations  with  presumed  risk  features  for  psychosis  with  the  aim  of
furthering the understanding of vulnerability to psychotic disorders among
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middle-aged subjects in a population-based study design. In two substudies,
cognitive performance and the presence of anhedonia, one of the negative
symptoms in schizophrenia, are studied among healthy, non-psychotic
members from families with schizophrenia. Two other substudies focus on
groups of middle-aged adults with psychotic-like or manic-like experiences
(PLEs or MLEs) from a population-based survey. Cognitive performance and
psychosocial functioning are explored at baseline, with an eleven-year follow-
up in order to study whether PLEs, MLEs or cognitive performance at
baseline predict future psychosis.
1.1 Psychotic disorders
The lifetime prevalence of psychotic disorders in Finland is 3.5 per cent, and
the most common psychotic disorder is schizophrenia with a lifetime
prevalence of one per cent (Perälä et al. 2007). The prevalence in Finland is
somewhat higher than internationally (median 0.4 per cent, Saha et al.
2005). Schizophrenia is one of the main contributors to the global burden of
disease (WHO, 2008) and is among the leading causes of disability (WHO,
2008; Wittchen et al. 2011). The incidence of psychotic disorders peaks in
young adulthood. The amount of suffering and distress caused by these
disorders is enormous for the patients themselves as well as for their
families.
    Psychotic disorders are characterized by behaviours and experiences
that severely interfere with the understanding of reality. Psychotic
symptoms, the central features of schizophrenia and other non-affective
psychoses, consist of delusions (false beliefs), hallucinations (false
perceptions) and disorganization (disturbed and confused thoughts, speech
or behaviour), which are called positive symptoms (Andreasen, 1984).
Particularly in schizophrenia, negative symptoms are common and often
prominent. Negative symptoms are functions that are normally present in
healthy persons but diminished or absent in persons with schizophrenia
(Andreasen, 1983). They include anhedonia, a diminished ability to
experience pleasure, flattened affect, a withdrawal from social relations (even
friends and family) and impoverishment of speech and thought (Andreasen,
1983; APA, 2013).
    Patients with a psychotic disorder often have cognitive deficits of
differing  severity  (van  Os  et  al.  2008).  These  are  most  severe  in
schizophrenia (Whyte et al. 2005a; Tuulio-Henriksson et al. 2011) and
typically milder and at least partly state dependent in bipolar disorder
(Krabbendam et al. 2005; Bearden et al. 2010). Studies on relatives of
patients  with  schizophrenia  (Whyte  et  al.  2005b;  Tuulio-Henriksson  et  al.
2003)  and  bipolar  disorder  (McIntosh  et  al.  2005;  Antila  et  al.  2009)  have
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shown that they also have similar, although milder, cognitive deficits to their
affected relatives, suggesting that these trait-like cognitive features relate to a
shared  genetic  vulnerability  to  these  disorders  (Faraone  et  al.  2002;
Gottesman et al. 2003). Manifestation of cognitive symptoms and their
severity  varies  across  individuals  (Barch,  2005;  Delawalla  et  al.  2006)  but
they most typically persist with relative stability over time with most
deterioration occurring around the onset of psychotic symptoms (Tandon et
al. 2009).
    Because of the distress and suffering related to psychotic disorders,
finding  ways  to  identify  those  with  an  elevated  risk  for  future  psychosis
before full onset is highly relevant. In adolescents and young adults with an
elevated risk for psychosis, early psychosocial interventions and
antipsychotic treatment have been found to even prevent (Preti and Cella,
2010) or at least delay the onset of psychosis (van der Gaag et al. 2013). In
the event of an outbreak of a psychotic disorder, early intervention may
decrease  symptom severity  (Bird  et  al.  2010)  and  improve  the  prognosis  of
psychosis (van der Gaag et al. 2014).
    Diagnosis  of  a  psychotic  disorder  is  based  on  an  assessment  of  the
presence  of  specific  symptoms.  Due  to  a  lack  of  biological  tests,  differential
diagnosis of psychotic disorders is often difficult. Currently, the International
Statistical Classification of Diseases and Related Health Problems, 10th
Edition  (ICD-10,  WHO,  1992)  and  the  4th and  5th editions of the Diagnostic
and Statistical Manual of Mental Disorders (DSM, APA, 2000; 2013) are the
most used classification guidelines in diagnosing schizophrenia and other
psychoses.
1.1.1 Schizophrenia
Schizophrenia is characterized by delusions, hallucinations, disorganized
speech and behaviour as well as negative symptoms and marked cognitive
information processing deficits interfering with the ability for independent
functioning, socially and occupationally (APA, 2000; APA, 2013). In
schizophrenia, thinking ability, perception and emotional functioning are
often fundamentally compromised. Diagnostic criteria for schizophrenia
according to the Diagnostic and Statistical Manual of Mental Disorders, 4th
edition (DSM-IV, APA, 2000) which was used in the current studies is
presented in Table 1.
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Recently, the definitions of different psychotic disorders have been updated
in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition
(DSM-5, APA, 2013). Regarding schizophrenia in DSM-5, the so-called first-
rank symptoms (e.g. running commentary voices, bizarre delusions,
delusions of control, delusional perception, thought withdrawal, insertion or
broadcasting) alone are not enough to fulfill criteria A, because evidence for
first-rank symptoms as the main differentiating symptoms between
schizophrenia and other psychoses is unclear (Nordgaard et al. 2008). This
has additional influence on diagnostic criteria for schizoaffective,















- Grossly disorganized or catatonic behaviour
- Negative symptoms
Only one of the criterion symptoms is required if delusions are bizarre or
hallucinations consist of a voice keeping up a running commentary on the





One or more major areas of functioning (work, interpersonal relations, self-care)
are markedly below the level achieved prior the onset of symptoms, for a
significant proportion of time
Duration Signs of the disorder persist for at least 6 months. This period must include at
least one month of symptoms that meet criterion A (active-phase symptoms,
less  than  one  month  if  successfully  treated).  Also,  this  6-month  period  may
include periods of prodromal and residual symptoms
Exclusion Schizoaffective disorder and mood disorder with psychotic features





In case of a history of autistic disorder or another pervasive developmental
disorder, the additional diagnosis of schizophrenia is made only if prominent
delusions or hallucinations are present for at least one month (less if
successfully treated)
1 American Psychiatric Association, 2000
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schizophreniform and delusional disorders. In schizoaffective disorder the
relationship between mood symptoms and psychotic symptoms has been
clarified:  symptoms which fulfil  the criteria for a  mood disorder need to be
present  for  the  majority  of  the  total  duration  of  the  active  and  the  residual
portions of the illness (over 50%). In addition, DSM-5 includes a rating scale
for the dimensional assessment of domains of psychopathology in psychosis,
which  consists  of  the  five  diagnostic  criteria  for  schizophrenia
(hallucinations, delusions, disorganized speech, abnormal psychomotor
behaviour and negative symptoms) as well as dimensions of depression,
mania and impaired cognition (Barch et al. 2013).
    People at risk of developing schizophrenia often already show subtle
cognitive, social and motor dysfunction in childhood, followed by anxiety,
low mood and social withdrawal in adolescence (Addington et al. 2016;
Fusar-Poli  et  al.  2013).  These  early  signs  may  be  followed  by  prodromal
symptoms,  generally  leading  to  the  onset  of  first  psychotic  episode  (Howes
and Murray, 2014). Prodromal symptoms disrupt daily life. These symptoms
often include sleeping disturbances, depressive mood and social withdrawal
as well as positive symptoms such as perceptual abnormalities (Yung et al.
2007;  Brewer  et  al.  2005;  Hafner  et  al.  2013).  Additionally,  the  level  of
cognitive  functioning  may  decline  before  manifestation  of  the  disorder
(Seidman et al. 2016). Deterioration in cognitive functioning during
adolescence has been found to predict future schizophrenia or other non-
affective psychoses (MacCabe et al. 2013).
The course of schizophrenia is individual, typically fluctuating with
enduring residual positive and negative symptoms interspersed by acute
exacerbations of positive symptoms. An essential element in treatment is
antipsychotic medication for reducing psychotic symptoms and preventing
relapse (Leucht et al. 2012). In addition to psychopharmacology, treatment
typically includes an individually tailored combination of psychoeducation,
family intervention, cognitive-behavioural therapy (Bird et al. 2010), and
cognitive remediation may also be recommended (Wykes et al. 2011; Mander
and  Kingdon,  2015;  Ventura  et  al.  2017).  In  schizophrenia,  duration  of  the
active disorder is usually longer than in other psychotic disorders, and the
cognitive decline is typically more severe (APA, 2013). Younger age at onset
has been found to predict poorer prognosis: more hospitalizations, negative
symptoms and relapses as well as poorer social/occupational functioning
(Immonen et al. 2017). Even though most subjects with schizophrenia
manage  to  overcome  the  psychotic  episodes  with  optimal  treatment,
cognitive, functional and emotional impairment often persist with either
progressive course or more stable deficit, with only 13.5% median recovery
estimate according to a recent meta-analysis (Jääskeläinen et al. 2013).
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1.1.2 Schizophreniform disorder
Symptoms of schizophreniform disorder are basically identical to those of
schizophrenia, with the exceptions being that the duration of symptoms is at
least one month and full recovery is in 6 months. Additionally, decline in
functioning is not required in the diagnostic criteria. The diagnosis of
schizophreniform disorder is often provisional and if the symptoms persist
over six months, the diagnosis is changed to schizophrenia (APA, 2000).
1.1.3 Schizoaffective disorder
In schizoaffective disorder, the full criteria of both the active phase of
schizophrenia  and  a  mood episode  must  be  met.  A  mood episode  may  be  a
major depressive episode, manic or mixed episode. Additionally, during the
same period of illness, at least a two-week period with delusions and
hallucinations, but without prominent mood symptoms, should exist. In
schizoaffective disorder, symptoms that meet the diagnostic criteria for a
mood episode must be present for a substantial proportion of the total
duration of active and residual periods (APA, 2000).
1.1.4 Mood disorders with psychotic features
Mood disorders with psychotic features, i.e. affective psychoses, have been
regarded as conditions in which psychotic features may be present as an
associated feature (APA, 2013). According to the American Psychiatric
Association (APA, 2000; APA, 2013), bipolar I disorder is a mental disorder
characterized by one or more manic or mixed episodes, usually accompanied
by major depressive episodes. Psychotic symptoms can occur during manic,
mixed or depressive episodes. In general, psychotic symptoms in mood
disorders have been found to be associated with more severe
symptomatology, worse outcome and psychosocial functioning when
compared  with  mood  disorders  without  psychotic  symptoms  (Keller  et  al.
2007; Matthews et al. 2009). The psychotic symptoms included in the
diagnostic criteria for psychotic mood disorders are delusions or
hallucinations, while, for example, disorganized behaviour is not included in
this  context  (Hua  et  al.  2011;  Tandon  et  al.  2012).  Bipolar  II  disorder  is
characterized by at least one hypomanic but no manic or mixed episodes, and
one major depressive episode, which can present with psychotic features
(APA, 2000).
    The  course  of  illness  in  bipolar  I  disorder  is  typically  characterized  by
recurrent manic and depressive episodes, often accompanied by periods of
normal mood or subthreshold mood symptoms between episodes (Judd et al.
2003;  Joffe  et  al.  2004).  The  disorder  is  usually  chronic,  and  causes  a
disability on functional outcome, psychosocial factors and quality for life for
the patients (Vos and Mathers, 2000; Parikh et al. 2010). Psychotic
symptoms have been found to predict poorer outcome (Kendler, 2013). In a
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Finnish  5-year  longitudinal  study,  151  patients  with  bipolar  I  or  bipolar  II
disorder were followed in a naturalistic, secondary-care cohort reflecting
current  treatment  era  (Pallaskorpi  et  al.  2015).  They  found that  at  the  five-
year follow-up 59.8% of subjects were euthymic, and the rest were with a
current episode mostly with depressive symptoms (17.9%) or with a major
depressive episode (16.1%). By five years, 96% had reached full remission but
most of the subjects had several recurrences. Having lifetime psychotic
symptoms was predictive of shorter time to first recurrence (after reaching
remission from the index episode).
   Although typically a non-psychotic mental disorder, major depressive
disorder may also manifest with psychotic features. The presence of
psychotic symptoms has been associated with poorer outcome (Perlis, 2010;
APA, 2013). In an American study with different ethnic/racial groups,
depressive remission rates were worse in subjects with auditory/visual
hallucinations, and paranoid ideation had a negative impact on remission
(Cassano et al. 2013).
1.1.5 Other psychotic disorders
According to the American Psychiatric Association (2000), in delusional
disorder one or more non-bizarre delusion exists at least for one month. No
other  prominent  active  phase  symptoms  of  schizophrenia,  except
tactile/olfactory hallucinations (if related to delusional theme), should be
present. Functioning is not markedly impaired and behaviour is not
obviously odd or bizarre. Brief psychotic disorder refers to a sudden onset of
psychotic  symptoms  which  last  at  least  one  day  but  no  longer  than  one
month. Full remission and return to premorbid level of functioning should be
achieved. Psychotic disorder not otherwise specified refers to a condition
where psychotic symptoms occur but a specific diagnosis cannot be made due
to inadequate or contradictory information or symptoms and otherwise do
not meet full criteria for a specific psychotic disorder. In psychosis  due  to
substance use prominent delusions or hallucinations are judged to be a direct
physiological effect of substance (alcohol or other substance of abuse) use or
withdrawal, medication or toxin exposure. In psychosis due to a general
medical condition the essential feature is prominent hallucinations or
delusions due to direct physiological effects of a general medical condition.
Clear temporal association must be found between said condition and the
onset of psychotic disturbance, for example, central nervous system
infection, temporal lobe epilepsy and any severe medical condition requiring
treatment in an intensive care unit (APA, 2000).
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1.2 Aetiology of psychotic disorders
1.2.1 Genetic influence
Psychotic disorders are complex, multifactorial disorders with many gene
and several environmental risk factors that have an interactive effect when
they exist simultaneously in the same individual (Gottesman et al. 2003;
Cardno and Owen, 2014). Both genetic disposition and environmental factors
contribute to the development of psychiatric disorders (Kim and Lee, 2016;
Franke et al. 2016). Family history of psychosis has been used as a measure
of  genetic  risk,  even  though  it  is  only  an  indirect  measure  (van  Os  et  al.
2008). Still, it is considered to be a very strong risk factor for future
psychosis. Approximately 10% of people with a family history of psychosis
develop a psychosis themselves (Cardno and Owen, 2014; Liu et al. 2015).
    Genetic vulnerability plays an important role especially in the aetiology
of severe disorders such as schizophrenia and bipolar disorder (Uher, 2014;
Bipolar Disorder and Schizophrenia Working Group of the Psychiatric
Genomics Consortium, 2018). The heritability, i.e. the proportion of variance
explained  by  genetic  factors  in  a  certain  population,  is  estimated  to  be
approximately 60-80% for schizophrenia (Cardno and Owen, 2014; Cardno
et al. 1999; Cardno et al. 2002) and bipolar I disorder (Kieseppa et al. 2004;
Song et al. 2015). Additionally, in a large Swedish population-based family
study with hospital discharge register data heritability for schizophrenia was
found to be 64% and for bipolar disorder 64% (Lichtenstein et al. 2009).
    Since 2009,  several  significant findings have been made in the genetic
research of schizophrenia. It has been found that so-called common variants,
which  are  common  in  the  population  and  not  disease  causing  individually,
may cumulatively lead to susceptibility to complex polygenic diseases such as
schizophrenia (Cardno and Owen, 2014; Pardinas et al 2018). Recently, the
Psychiatric Genomics Consortium reported altogether 179 independent
associations meeting genome-wide significance that contribute to disease
risk in schizophrenia (Pardinas et al. 2018).
In addition to the aforementioned polygenic common variants, very rare
copy number variants (CNVs), that are present in a very small proportion of
the population but have a several-fold effect on schizophrenia risk, have been
identified from genome-wide association studies (Malhotra and Sebat, 2012).
A recent study by the Psychiatric Genomics Consortium confirmed eight
deletions or duplications to have genome-wide significant association with
schizophrenia (https://www.ncbi.nlm.nih.gov/pubmed/27869829). While
copy number variants are found only in a small fraction of patients with
schizophrenia,  in  this  population  they  are  the  strongest  contributors  to  the
pathogenesis of the disease (Stefansson et al. 2014). Also, exome and whole-
genome sequencing studies have allowed the identification of first rare
mutations in single genes (loss-of-function variants) which are associated
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with up to a 35-fold increased risk of schizophrenia (Singh et al. 2016;
Steinberg et al. 2017; Singh et al. 2017).
1.2.2 Environmental influence
Genetic vulnerability interacting with adverse environmental effects may be a
pathway leading to the development of a psychotic disorder (Uher, 2014).
Environmental factors can be pre- or perinatal or occur later in life (Liu et al.
2015; Walder et al. 2014). While there are several environmental factors that
have been found to be associated with an increased risk for psychosis, it
should be noted that in each individual different environmental exposures
can precipitate and influence one another. The Vulnerability-Stress model of
schizophrenia suggests that genetic factors and/or perinatal risk factors
result in increased vulnerability to later environmental risk factors (Van
Winkel et al. 2010). This in turn triggers psychotic symptoms if the threshold
of psychosis is met (van Os et al. 2008; Tsuang et al. 2004). The progressive
neurodevelopmental model suggests that schizophrenia results from
abnormal brain development starting from the fetal period (Rapoport et al.
2012) and affecting brain maturation during childhood and adolescence
(Nour  and  Howes,  2015).  Table  2  presents  environmental  factors  for  which
gene-environment interplay has been suggested.
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Table 2. Environmental exposures for psychosis (modified from van Winkel et al, 2010)
Variables
Fetal life Pregnancy complications (fetal hypoxia, fetal folate
deficiency)
Prenatal maternal infection, stress or folate deficiency
Advanced paternal age
Prenatal exposure to chemical agents (e.g. lead)
Early life Early rearing environment (institutional care, inadequate
parenting)
Childhood trauma (abuse, neglect)
Middle childhood/adolescence Urban environment (level of population density, or size of






Wider social environment Neighbourhood measures of social fragmentation, social
capital and social deprivation
Microenvironment in daily life Small daily life stressors (assessed with momentary
assessment technology) subtly impacting affect, salience
and reward
1.2.3 Brain imaging findings
Studies using neuroimaging have found structural brain alterations in
patients with psychotic disorders that may have already been present at onset
of psychosis (Crossley et al. 2016; Schmidt et al. 2016). Magnetic resonance
imaging (MRI) is the typical technology used in these studies. However, no
specific diagnostic or prognostic biomarkers that would have clinical utility
have been found (Fusar-Poli and Meyer-Lindenberg, 2016). A recent meta-
analysis of structural studies across several psychiatric disorders
(schizophrenia, bipolar disorder, depression, anxiety, addiction and
obsessive-compulsive disorder) found converging grey matter loss in the
same brain areas, suggesting that diagnosis-specific effects are few and that
there are shared neural substrates across psychopathology (Goodkind et al.
2015). There are also several confounding factors in interpreting the results
from MRI studies in populations with psychotic disorders: in addition to the
effects of chronicity of illness (severity of psychotic symptoms) or
antipsychotic exposure (Huhtaniska et al. 2017), factors such as age,
smoking, substance abuse and other cardiovascular risk factors can alter
brain structures (Fusar-Poli and Meyer-Lindenberg, 2016).
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In addition to the methods of structural neuroimaging, positron emission
tomography (PET) and single photon emission computed tomography
(SPECT) have been used to investigate the nature of dopaminergic
dysfunction  in  schizophrenia  (Juckel,  2016).  Based  on  these  studies,  one
finding is the dysfunction of the striatal dopaminergic system that produces
an increase in presynaptic synthesis of dopamine in patients with
schizophrenia (Howes et al. 2012).
Studies using functional magnetic resonance imaging (fMRI) have
identified abnormal activations in a wide diversity of brain regions and
across different cognitive domains (Crossley et al. 2016). Compared to
controls, patients with schizophrenia can have either reduced or greater
activation (Callicott et al. 2000; Surguladze et al. 2006), or a combination of
both (Quintana et al. 2003), depending on the task and the regions studied.
In schizophrenia, functional connectivity (interactions between different
brain regions) has been found to differ from that of normal subjects with
task-specific under-activation accompanied by over-activation of
topologically central, less functionally specialized network nodes, possibly
representing a compensatory response (Crossley et al. 2016).
1.3 Negative symptoms and anhedonia
Negative symptoms such as blunted affect, alogia, asociality, avolition and
anhedonia reflect a diminishment or loss of certain areas of functioning, and
are  often  part  of  the  clinical  picture  in  schizophrenia  (Andreasen,  1983;
Lincoln et al. 2017). Negative symptoms have often received less attention in
research possibly because they are less salient, less responsive to
antipsychotic medication and more difficult to assess due to their
relationship  with  other  features  of  the  disorder,  such  as  depression,
disorganization and cognitive deficits, as well as side effects of antipsychotic
medication  (Aleman  et  al.  2017).  However,  negative  symptoms  have  a
marked  impact  on  social  functioning  and  quality  of  life  in  patients  with
schizophrenia (Robertson et al. 2014; Fervaha et al. 2014).
 Anhedonia refers to inability or diminished ability to experience pleasure
(Horan  et  al.  2006b),  and  it  has  been  considered  a  vulnerability  factor  for
schizophrenia. Chapman et al. (1976) introduced distinctions between
physical anhedonia (e.g. pleasure from eating, touching, smell) and social
anhedonia (pleasure from being with or communicating with other people).
He and colleagues developed several scales in order to measure personality
traits indicating predisposition to psychosis (Chapman et al. 1994). It has
been found that persons with schizophrenia have elevated levels of
anhedonia both in early and later, more chronic states of the disorder (Horan
et al. 2006b; Blanchard et al. 2001). Anhedonia may also be present before
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the illness onset as a risk factor (Gooding et al. 2006). Some studies have
found elevated levels of social (Kendler et al. 1996) and physical anhedonia
(Franke et al. 1994) in first-degree relatives of schizophrenia patients
suggesting a familial liability to anhedonia. However, there are also studies
that found similar levels of anhedonia in relatives and controls (Erlenmeyer-
Kimling et al. 1993a; Craver and Pogue-Geile, 1999). Different methodology
and inclusion criteria for relatives/patients may explain inconsistent findings
(Schürhoff et al. 2003).
Subclinical psychotic experiences have been found to more likely predict
transition to psychosis when accompanied by social anhedonia and
withdrawal (Ruhrmann et al. 2010; Velthorst et al. 2012). However, there is a
marked heterogeneity in manifestation of anhedonia, and not all patients
with schizophrenia experience anhedonia. It has been estimated that
approximately one-half of the patients have anhedonia levels within the same
range that has been found in healthy subjects (Schürhoff et al. 2003). In the
course of the illness, anhedonia seems to remain rather stable, regardless of
fluctuation of positive psychotic symptoms and other severity features of the
illness. In a 10-year follow-up, both a stable trait component as well as a
more variable state component of anhedonia was found, where the state
component correlated with depressive symptoms (Herbener and Harrow,
2002).
However, there are several factors which may influence the level of
reported anhedonia of the patients. The experience of anhedonia may be
modified by antipsychotic medication that modifies motivational salience by
blocking dopamine D2 receptors, resulting in a loss of drive, energy and
motivation, apathy and anhedonia (Juckel, 2016). This is most evident with
the so-called typical antipsychotics (first-generation antipsychotics), while
the new atypical or second-generation antipsychotics only partially block D2
receptors (Meltzer, 2013; Juckel, 2016).
Additionally, the methods used in assessing anhedonia may vary. In
clinical tradition, anhedonia has often been evaluated based on the nature of
the stimulus (e.g. source of pleasure). An inability to experience pleasure
from physical sources (physical anhedonia) and an inability to experience
pleasure from social sources/interactions (social anhedonia) are considered
to be separate domains (Wolf, 2006). When assessed using self-report
questionnaires, patients with schizophrenia on average reported diminished
pleasure  from  both  social  and  physical  sources.  Despite  this  there  was  no
strong correlation between physical and social anhedonia (approximately
.05) (Katsanis et al. 1990) suggesting substantial independence between
these domains. Gender and education have also been found to have an effect
on the amount of anhedonia reported using the Chapman Scales, with men
scoring higher in physical and social anhedonia (Miettunen and
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Jääskeläinen, 2010) and subjects with lower education scoring higher in all
the scales (Miettunen et al. 2010).
    Research has tried to distinguish different types of anhedonia according
to the degree of immediacy between the presented stimulus and the
experience  of  pleasure  (Cohen  et  al.  2012).  Anticipatory  pleasure  (“I  will
enjoy  it”),  remembered  (“I  enjoyed  it”)  and  trait  pleasure  (“I  usually  enjoy
it”) are hedonic experiences removed from the time of the stimulus (Wolf,
2006; Gard et al. 2007). Judgements of anticipatory, remembered and trait
pleasure and the emotional experience associated with these judgements are
typically measured with either self-report or interview-rated questionnaires
(Blanchard and Cohen, 2006; Horan et al. 2008a). They require effective
enough cognitive processes, including memory, insight, generalization and
prediction, that are often impaired in schizophrenia (Horan et al. 2006a). On
the other hand, consummatory pleasure occurs immediately at the time of
the stimulus with automatic emotional response representing “in the
moment” or state emotional experience (Cohen et al. 2012; Cohen and
Minor, 2010). Studies with self-report scales designed to separately assess
anticipatory and consummatory pleasure have found that patients with
schizophrenia reported more anhedonia only in relation to anticipatory items
(Gard et al. 2007). Examinations of in the moment or state emotions under
laboratory conditions have found that individuals with schizophrenia report
experiencing  normal  levels  of  pleasant  emotions  (Kring  and  Moran,  2008;
Cohen et al. 2011). It has also been found that schizophrenia patients are able
to differentiate a loss of emotion from depressive mood (Dollfus and Lyne,
2016). Advances in neuroscience have identified distinct neural pathways
related to the experience of anticipatory pleasure and consummatory
pleasure (Cohen et al. 2011). Additionally, dopamine has been shown to be
strongly linked to anticipatory rather than consummatory pleasure (Berridge,
2007) while the experience of consummatory pleasure has been linked to
serotonin and opioid systems (Schulze-Rauschenbach et al. 2015; Wise,
2002).
1.4 Psychotic-like symptoms
1.4.1 Psychotic-like experiences in the general population
Psychotic-like thoughts or perceptions are not present only among people
with psychotic illnesses or with people about to convert to one. People from
the general population may also experience psychotic-like experiences
(PLEs), such as paranoid thinking or abnormal perceptual experiences, that
are qualitatively similar but milder than the experiences of patients with a
diagnosed  psychotic  disorder  (Linscott  and  van  Os,  2013).  PLEs  may  be
bizarre, cause distress, draw attention or prompt help-seeking, but not
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necessarily. They comprise phenomena which may be interpreted as
clinically relevant symptoms or as subclinical, below a threshold of clinical
relevance (van Os et al. 2008; Linscott and van Os, 2013). Several large
population studies indicate that PLEs can be measured in the general
population and that they most likely represent the behavioural manifestation
of distributed multifactorial (genetic and non-genetic) risk for psychosis (van
Os and Reininghaus, 2016), supporting the continuum view of psychosis.
Subclinical psychotic-like experiences are rather common in the general
population with a median annual prevalence at about 7% (Linscott and van
Os, 2013), which is greater than the 3% prevalence of psychotic disorders
(Perälä et al. 2007). In general, PLEs are transitory in most of the cases
(about 80%), but around 20% develop persistent psychotic experiences and
7% of those a psychotic disorder with an annual transition rate below 1%
(Linscott and van Os, 2013; Kaymaz et al. 2012).
1.4.2 PLEs and risk for future psychosis
Psychotic-like symptoms have been found to be associated with an elevated
risk  for  future  psychotic  disorders  (Dominguez  et  al.  2011;  Werbeloff  et  al.
2012), as well as for depression and anxiety disorders (Wigman et al. 2012).
However, this has mostly been studied in adolescents and young adults with
clinical populations in Clinical High Risk (CHR) settings (Murray and Jones,
2012; Fusar-Poli et al. 2013a). The basic concepts of psychosis risk research
are presented in Table 3.
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Table 3. Definitions of concepts in psychosis risk research
Concept Definition




Attenuated positive symptoms not severe enough to reach psychotic
threshold
Prodrome Symptomatic phase before onset of a full psychosis. A retrospective
concept
Basic symptoms Early prodromal phase with subtle, self-experienced anomalies in
cognition and perception
Clinical high-risk syndrome Symptomatic approach in psychosis risk research. Consists of:
- attenuated positive symptoms or
- brief limited intermittent psychotic symptoms or
- lowered functioning with schizotypal personality or familial risk
to psychosis
Familial (genetic) high risk Family history of psychosis
CHR is a prospective concept which aims to predict the risk of transition to
psychosis by clinically significant risk symptoms (Fusar-Poli et al. 2013;
Addington and Heinssen, 2012). To be classified as having a clinical high risk
(CHR)  for  psychosis,  one  or  more  of  the  risk  criteria  needs  to  be  fulfilled:
subject has attenuated psychotic symptoms, brief limited intermittent
psychotic symptoms, and/or genetic risk and deterioration of functioning
(Yung  and  McGorry,  1996;  Fusar-Poli  et  al.  2016).  Additionally,  a
comparably high risk for psychosis has been independently associated with
an earlier phase of prodromal psychosis (Fusar-Poli et al. 2013). The concept
of CHR is used in both academic studies and clinical practice to help identify
adolescents and young adults at risk for future psychotic disorders (Yung et
al. 2012; Fusar-Poli et al. 2013). Among individuals aged 12-35 years with a
recent  onset  of  CHR  symptoms,  20-35%  go  on  to  develop  a  full  psychotic
disorder  over  a  2-year  period  (Fusar-Poli  et  al.  2012;  Cannon  et  al.  2016).
While the concept of a prodrome refers to the symptomatic period before full
onset  of  first  psychotic  episode,  CHR  does  not  predetermine  future
psychosis, as the possible risk symptoms may resolve spontaneously or with
early psychiatric intervention (Fusar-Poli et al. 2012; Cannon et al. 2007).
The impact that different CHR symptoms have for the transition to
psychosis has been found to vary. In a recent meta-analysis, a subgroup of
subjects having brief limited intermittent psychotic symptoms were found to
have  a  higher  risk  for  psychosis  than  those  with  attenuated  psychotic
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symptoms (Fusar-Poli et al. 2016). In this meta-analysis, the familial risk and
deterioration  subgroups  were  not  found  to  have  an  enhanced  risk  for
psychosis.  However,  it  has  been  suggested  that  the  impact  of  familial
(indicative  of  genetic)  risk  might  only  be  evident  in  a  longer  follow-up  and
after the age of 20 years (Rasic et al. 2014), warranting long follow-up
periods of risk subjects.
    The prevalence of self-reported PLEs declines between ages of 20 and
40 (Rossler et al. 2007). This may suggest true variation, or partly reflect the
fact that those adolescents with PLEs indicative of future psychosis have
already developed an illness. Additionally, with increasing age,
understanding of the items in questionnaires for PLEs may increase and thus
decrease the false positive answers (Therman et al. 2014).
Most of the studies on the significance of PLEs for future psychosis have
been conducted in clinical settings. However, there has arisen an interest on
PLEs in non-help-seeking general populations (van Os and Reininghaus,
2016). Among subjects with PLEs, with and without need of care, deficits in
cognitive processing and ways to appraise and respond to PLEs have been
found  to  differ  between  patients  with  psychotic  disorders,  those  with  a
heightened risk for a psychotic disorder and non-help-seeking (non-clinical)
group (Peters et al. 2016). Help-seeking and need of care were found to be
more commonly associated with perceived cognitive symptoms, such as
inability to concentrate and loss of automaticity of thinking skills, even
though the reported PLEs were similar to those reported by persons without
the need of care (Brett et al. 2015). Predictors of high distress relating to
PLEs were changes in awareness and cognitive processes, appraisals of
experiences being caused by other people and greater attempted control over
experiences, while predictors of lower distress were “spiritual” appraisals of
experiences, greater perceived social support and understanding, greater
perceived controllability and neutral response as a reaction to PLEs (Brett et
al. 2014).
In comparison to patients with psychosis, persons with persistent
psychotic experiences but without need of care have been found to have
greater cognitive resources (self-report of subjective difficulties), to be less
socially disadvantaged and also to have more socially valued roles (Peters et
al. 2016). This suggests that a lack of social and environmental adversity and
good enough cognitive functioning may be protective against malign
outcomes of psychotic experiences. These findings also support models in
which environmental and psychological factors interact with biological
processes in the aetiology of psychosis. Interestingly, cognitive behavioural
therapy, which has been found to be useful to patients with psychosis, aims
at decreasing distress by modifying the patient’s beliefs concerning their
anomalous experiences (Mander and Kingdon, 2015).
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1.4.3 Manic-like experiences
Finding means for the early detection of psychotic disorders, particularly
schizophrenia, has been studied since the 1990s. Recently, interest has arisen
on subthreshold manic-like experiences (MLEs) or manic-like affective
symptoms,  which  do  not  fulfil  criteria  of  bipolar  disorder  or  other  affective
psychoses as predictors for these illnesses in the future (Bechdolf et al. 2014).
Clinical studies have revealed a pattern of symptoms preceding the onset of
bipolar disorder, of which mood lability and/or mood swings and/or
cyclothymic features, depressive mood, racing thoughts, irritability and
physical agitation are most commonly reported (Skjelstad et al. 2010; Howes
and  Falkenberg,  2011;  Bechdolf  et  al.  2012).  Early  intervention  has  been
found to lessen the severity, prevent progression and potentially delay or
even prevent the onset of full-blown bipolar disorder (Correll et al. 2007;
Salvadore  et  al.  2008).  In  previous  studies  that  have  used  the  Hypomanic
Personality Scale (Eckblad and Chapman, 1986), it has been found that the
scale predicted bipolar disorder and major depressive episodes (Kwapil et al.
2000) and psychosis (Miettunen et al. 2011) in young adults. It has been
suggested that subthreshold affective symptoms and substance use disorders
predict bipolar disorder among help-seeking young people in a 12-month
follow-up (Ratheesh et al. 2015b), but there are only few studies that have
addressed this and no established tools to identify individuals at risk for
developing bipolar disorder (Bechdolf et al. 2014).
1.4.4 Assessment of psychotic- or manic-like experiences
Variations in assessment methodology and populations under study
(particularly clinical vs. general population) are notable limitations in
making direct comparisons on findings of PLEs or manic-like experiences.
Presently, several psychological and psychiatric instruments are used for
identifying subjects with different psychiatric disorders, as well as for
recognizing  those  at  risk  for  future  disorders  (APA,  2000;  Miettunen  et  al.
2011;  Ratheesh  et  al.  2015a).  The  methods  used  for  assessing  psychotic
experiences also seem to affect the prevalence estimates, with higher
prevalence found in studies using self-report methods than in those using
interview-based methods (van Os, 2016).  Additionally, response frequencies
for  different  items  probing  PLEs  may  vary  considerably  even  in  general
population samples, raising doubts about using a single summary score of
the PLE questionnaires (Therman, 2013). In a population-based sample of
Swedish women over 41 years of age, response frequencies to “positive”
(indicative  of  PLE)  items  on  the  used  measure  of  PLEs,  the  Community
Assessment of Psychic Experiences, varied from 0.5% (voices conversing) to
over 50% (false appearances and telepathy) (Therman, 2013).
Cultural differences and possibly socioeconomic factors may contribute to
the way people understand the questions and the situation when these
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experiences are measured. There is evidence that the prevalence of PLEs
reported by people varies across countries (Nuevo et al. 2012). Higher
lifetime  prevalence  estimates  have  been  found  in  middle-  and  high-income
countries than in low-income countries (McGrath et al. 2015), as well as
findings that psychotic-like experiences are more common in ethnic minority
groups (Linscott and van Os, 2013a; Morgan et al. 2009).
1.5 Neuropsychology and the measurement of cognition
1.5.1 Neuropsychological assessment
Cognitive domains can be assessed with neuropsychological tests that are
standardized measures targeted for different aspects of cognitive processes
(Andrewes, 2016). When deficits in cognitive processing are assessed in
clinical practice, some formation of normal or prior level of functioning of
each patient must be achieved in order to evaluate the possible change in
patient’s performance (Lezak et al. 2004; Lezak et al. 2012). This level, the
comparison standard, may be normative (derived from appropriate
population) or individual (derived from patient’s history or present
characteristics). Performance in different tests also varies relating to age,
gender, education level and general mental ability as well as cultural
background, in addition to possible brain pathologies or conditions affecting
the efficiency of brain functioning, such as depression, anxiety or other
psychiatric conditions (Lezak et al. 2004). In clinical neuropsychological
assessment, both normative and individual comparison standards are used,
as appropriate for the function or activity being examined and the purpose of
the examination.
In research settings, the use of reliable and validated assessment methods
of cognition is equally important. Additionally, it is important to use control
groups that are of the same age and are recruited and tested with similar
methods and at the same time as the study subjects (Snitz et al. 2006).
1.5.2 Cognitive domains and cognition as a functional system
Generally, within each class of cognitive function a division may be made
between functions that mediate verbal/symbolic information and those that
deal with information that cannot be communicated with words or symbols,
such as complex visual or sound patterns. Even though different cognitive
functions can be conceptually distinguished, it is important to note that they
are interdependent and inextricably bound together. Different subclasses of
functions do differ from one other in their neuroanatomical organization and
in their behavioural expression, but at the same time share other basic
neuroanatomical and psychometrically measurable relationships within the
functional system (Andrewes, 2016; Lezak et al. 2004). Cognitive domains
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are shortly presented below. The domains relevant to this study are described
in more detail.
1.5.2.1 Perception
Perception includes the analysis of senses such as vision, audition, taste,
olfaction (smell) and tactile and other somatosensory stimulation. It is
differentiated from sensation (product of environmental stimulation prior to
its perceptual interpretation). Perception is a process comprising successive
and interactive stages. Those dealing with the simplest physical or sensory
characteristics (colour, shape, tone) come first and form the foundation for
more complex, higher levels of (e.g. semantic and visuoconceptual)
processing that integrate sensory stimuli with one another and successively
with past experiences, hence forming meaningful representations of things
(Andrewes, 2016). Normal perception is a complex process involving many
different aspects of brain function. Because of extensive cortical distribution
and complexity, perceptual functions are vulnerable to damage, and
depending on the location of an injury a wide range of impairments may
occur (Lezak et al. 2012; Andrewes, 2016).
1.5.2.2 Attention
Attention refers to a group of brain structures and their biochemical
substrates that act together in an integrated way to achieve an attentional
goal  (Andrewes,  2016).  They  can  be  described  as  the arousal system for
maintaining suitable cortical tone/vigilance according to environmental
demand; orientation system for detecting and orienting attention towards
novel/unpredictable stimuli; selective attention that allows focus on one task
and/or stimuli while ignoring others (at the expense of others) and an
executive attentional system which serves to control attention by inhibiting
and disinhibiting orientation responses and controlling selective attentional
system (Andrewes, 2016; Buschman and Kastner, 2015). Attention can be
switched, allowing focus on different tasks in quick succession in order to
maintain more than one task within a similar period of time. Attention and
most importantly deficits in attentional systems influence the efficiency of
other cognitive functions (Lezak et al. 2012; Andrewes, 2016). Attentional
systems are based on integrated activation on broad areas and connections of
the brain. Particularly fronto-parietal network and thalamo-cortical
interactions  have  crucial  roles  in  attention,  but  it  should  be  noted  that  the
nature of attentional processing is distributed throughout the brain and
sensitive to disturbance or damage (Andrewes, 2016; Dickinson et al. 2007;
Buschman and Kastner, 2015)
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1.5.2.3 Executive functions
Executive  functions  refer  to  a  broad  network  in  the  brain  that  has  a
governing, modifying and directing role with all other cognitive functions.
The  highest  demands  for  executive  functions  are  in  novel  or  complex
situations requiring initiative (Andrewes, 2016). They require self-initiated
flexible planning and organization of novel activities towards a self-generated
goal.  Even  in  simple  tasks  executive  functions  are  active  in  selecting,
maintaining and monitoring subprocesses relevant to the task at hand while
inhibiting irrelevant stimuli. Performance speed is  often  affected  by
executive deficits (Dickinson et al. 2007). Executive functions have
traditionally been associated with prefrontal cortex and the anterior
cingulate cortex, but parietal and temporal cortices also play a role, as well as
the important connections with subcortical areas and the cerebellum.
Damage to any of these areas or tracts connecting them may lead to executive
deficits (Lezak et al. 2012; Andrewes, 2016).
1.5.2.4 Memory and learning
Memory  is  a  complex  function  and  part  of  the  complexity  is  due  to  the
influence of other areas of cognition: impairment can happen due to
perceptual, attentional, verbal comprehension, executive or motor
dysfunction. Short-term memory refers to a simple temporary storage of
information (Baddeley, 2012). Working memory as  a  concept  refers  to  a
cognitive  function  which  combines  temporary  storage  with  conscious
inspection and manipulation of information. Efficient working memory
functioning requires attentional and executive resources. Working memory is
essential in learning new material and closely allied to attention (Baddeley,
2012; Andrewes, 2016). Intact working memory functioning relies on
dopaminergic regulation of neuronal networks, especially in the prefrontal
cortex (Goldman-Rakic, 1999; Ziermans, 2013). Long-term memory store
contains more permanent memories. Consolidation system is the mechanism
by which information is made more permanent within long-term memory
store. Learning new information that is momentarily maintained in working
memory may require modification of long-term memory store in a
purposeful process involving rehearsal and refreshing of the material, which
is  closely  tied  with  both  attention  and  executive  functions  (focusing  and
initiative in strategy formation). Consolidation system also has a role in
retrieval of information from the long-term memory store. The consolidation
system is represented by several brain structures: one of the most central
being hippocampus but also other structures connected to hippocampus (e.g.
the thalamus) are crucial for storing new memories (Andrewes, 2016). Most
of the memory research has been focused on the declarative memory
referring to the ability to learn about and to be able to remember facts,
objects and events (Lezak et al. 2012).
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1.5.2.5 Expressive functions
Expressive functions refer to means through which information can be
communicated or acted upon, such as speaking, drawing or writing, gestures
or movements. Deficits in language, constructional or spatial imaging
abilities  or  motor  impairment  may  affect  these  in  addition  to  deficits  in
executive functioning (Andrewes, 2016).
1.6 Cognitive deficits in study populations
1.6.1 Patients with psychotic disorders
Cognitive deficits compromising efficient information processing are typical
among subjects with psychotic disorders (van Os et al. 2008), and there are
findings indicative of associations of memory deficit and psychosis
susceptibility in general (McIntosh et al. 2005; Dominguez et al. 2009). The
most severe deficits in cognition are found among patients with
schizophrenia (Tuulio-Henriksson et al. 2011). In schizophrenia, a
generalized cognitive dysfunction is one of the core features of the disorder,
against which deficits in attention, executive functions and memory are
emphasized (Dickinson et al. 2004). In most cases cognitive deficits seem to
remain relatively stable or not deteriorate significantly over time (Heaton et
al. 2001; Kurtz, 2005). In a Finnish longitudinal general population cohort
study, the change in several dimensions of verbal learning and memory in a
nine-year follow-up was compared in subjects with schizophrenia and in
non-psychotic controls at midlife. Even though the subjects with
schizophrenia had poorer performance than the controls in several measures
of verbal learning and memory (both at baseline and at follow-up), there was
no  major  difference  in  the  amount  of  change  during  the  9-year  follow-up
(Rannikko et al. 2015a). A possible modifying factor affecting cognitive
functioning in subjects with schizophrenia, in addition of the illness itself, is
antipsychotic medication, especially with high doses or polypharmacy
(Torniainen et al. 2012; Ho et al. 2011) as well as with higher cumulative
lifetime  antipsychotic  dose  (Husa  et  al.  2017).  In  subjects  with  other  non-
affective psychoses, deficits in verbal memory and processing speed have
been found, but these were milder than with subjects with schizophrenia
(Tuulio-Henriksson et al. 2011). In a population-based study on subjects with
schizoaffective disorder, it was found that subjects with schizoaffective
disorder also had a generalized cognitive deficit when compared to control
subjects, but they outperformed subjects with schizophrenia in verbal ability,
processing speed, visual working memory and verbal memory (Torniainen et
al. 2012).
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Cognitive deficits have been found to be already present at premorbid and
prodromal phases of psychotic illness (Erlenmeyer-Kimling et al. 2000; Bora
et al. 2014). Several studies have examined the clinical course of cognitive
functioning in help-seeking subjects with prodromal symptoms. In meta-
analyses it has been found that at-risk individuals manifest similar, albeit
milder, cognitive deficits to subjects with first-episode and chronic
schizophrenia, with individuals who transition to psychosis presenting with
more  severe  deficits  at  intake  (Fusar-Poli  et  al.  2012;  Giuliano  et  al.  2012).
Cognitive decline usually occurs prior and during the onset of illness (Hoff et
al. 2005). In a review, global cognitive dysfunction was shown to be already
present in patients with first-episode psychosis with largest effect sizes for
verbal memory, executive function and general IQ (Aas et al. 2014).
Cognitive deficits are also found to be present among antipsychotic-naïve
patients (Fatouros-Bergman et al. 2014).
    Despite changes in assessment instruments and alterations in
diagnostic criteria, generalized cognitive dysfunction in schizophrenia has
been robustly demonstrated over time (Reichenberg 2010). In a large meta-
analytic review, the region of the world in which the cognitive functioning of
schizophrenia patients had been studied had only little impact on the effect
sizes reported, despite substantial geographic, cultural and linguistic
differences present in these groups of subjects (Schaefer et al. 2013).
    Deficits in cognition have also been found in subjects with bipolar
disorder and other affective psychoses, but these are usually less severe
(McIntosh et al. 2005; Trotta et al. 2015; Antila et al. 2007) and especially
with bipolar disorder, partly state dependent (Krabbendam et al. 2005;
Bearden et al. 2001). Medium effect size differences in cognitive domains of
executive function, memory and mental speed seem to separate
schizophrenia from bipolar disorder, with patients with schizophrenia having
more severe deficits (Bora et al. 2009). In a recent meta-analysis, executive
dysfunction was widespread in euthymic patients with bipolar disorder
(Mann-Wrobel et al. 2011), and previous meta-analyses have also shown
deficits in attention and verbal memory (Bora et al. 2009; Torres et al. 2010).
Mixed affective and psychotic features are also part of the clinical picture of
some of the patients with schizophrenia, and depression is commonly
observed in schizophrenia (Kempf et al. 2005). Regardless of diagnosis,
subjects with mixed psychotic and mood symptoms can have similar,
although milder, cognitive deficits to those observed in subjects with
schizophrenia with severe negative symptoms (Bora et al. 2009).
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1.6.2 Early course of cognitive deficits
Birth  cohort  and  conscript  studies  have  shown  that  subjects  who  later
develop  schizophrenia  often  have  early  cognitive  deficits,  suggesting  that
cognitive features are partly primary and not only secondary to psychotic
symptoms (Tiihonen et al. 2005; Koenen et al. 2009; Dickinson, 2014). It has
been found that subjects with later schizophrenia have small to medium
deficits across general and specific cognitive domains (Mollon and
Reichenberg, 2018). A similar type of cognitive profile has also been found in
other  non-affective  psychoses  (Kendler  et  al.  2016),  but  less  consistently  in
bipolar disorder (Trotta et al. 2015) and affective psychoses (Agnew-Blais et
al. 2015). Hence, aberrant neurodevelopmental processes may not be specific
to schizophrenia, and despite evidence for genetic overlap between
schizophrenia and bipolar disorder as well as major depression (Cross-
Disorder Group of the Psychiatric Genomics Consortium et al. 2013),
different profiles of premorbid cognitive functioning may suggest distinct
neurodevelopmental processes (Mollon and Reichenberg, 2018).
    In a recent meta-analysis it was found that persons who subsequently
developed schizophrenia had below average IQ at the age of 13 as well as
below average motor functioning at age 16, but no differences were found in
their general academic and mathematical achievement compared to those
who did not develop the disorder (Dickson et al. 2012). On the other hand, it
has been found that those who later develop bipolar disorder may even have
above average cognitive performance (MacCabe et al. 2013; Vreeker et al.
2016). In a longitudinal study on population-based cohorts of adolescent
boys  and  young  men  in  Sweden  (MacCabe  et  al.  2013),  a  decline  in  verbal
ability score between ages 13 and 18 years was the strongest predictor for
schizophrenia in adulthood. The results remained when adjusted for possible
confounders  such  as  urbanity,  parental  education  or  family  history  of
psychosis. The decline in verbal ability between ages 13 and 18 was also the
strongest predictor for other non-affective psychoses, but in this case a family
history  of  psychosis  also  emerged  as  a  significant  predictor.  In  the  same
cohort, individuals who later developed bipolar disorder outperformed
population norms on all tasks at all time points.
    In the Philadelphia Neurodevelopmental Cohort Study, Gur and
colleagues found that youths (between 8-21 years) who reported psychotic
symptoms had a cognitive age that was behind chronological age compared
to typically developed youths. Also, those with more significant psychiatric
symptoms  showed  greater  developmental  lag  (Gur  et  al.  2014).  The
developmental lag was found to be more pronounced in some cognitive
domains: complex cognition including verbal reasoning was delayed in the
psychotic symptoms group as early as at age 8 and remained delayed.
Additionally, a lag in social cognition was already detectable at that age. The
New Zealand longitudinal cohort study also suggests that children who later
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develop  schizophrenia  may  already  have  below  average  verbal  reasoning  in
childhood,  after  which  cognitive  dysfunction  may  also  manifest  in  working
memory, attention and processing speed functions (Reichenberg, 2010;
Reichenberg et al. 2002). In a group of patients with schizophrenia from
Finnish longitudinal general population cohort study, , lower premorbid
school marks at age 16 and lower education at age 34 predicted more
cognitive decline at 43 years of age than severity of illness at first episode or
later course of schizophrenia, supporting the neurodevelopmental course of
development of schizophrenia (Rannikko et al. 2015b).
1.6.3 Relatives of patients with psychotic disorders
Subtle cognitive deficits have been found in relatives of schizophrenia
patients, even though they do not have a psychotic disorder themselves (Snitz
et  al.  2006;  Cannon  et  al.  2000;  Tuulio-Henriksson  et  al.  2003).  These
findings suggest that cognitive deficits are markers of familial transmission
of liability to psychosis (Gottesman et al. 2003; Faraone et al. 2000).
Level of dysfunction may be associated with familial loading, since in
families with multiple affected individuals, cognitive deficits found in
relatives are more pronounced than in families with only one affected
individual (Tuulio-Henriksson et al. 2003; Faraone et al. 2000). In meta-
analyses, the largest differences between relatives of schizophrenia patients
and  controls  have  been  found  in  verbal  learning  and  executive  functioning
(Snitz  et  al.  2006;  Sitskoorn  et  al.  2004).  However,  at  least  partly  due  to
differences in methodology and study samples, the findings concerning
executive functioning have been somewhat inconsistent (Laurent et al.
2000).
Among non-psychotic relatives of patients with bipolar disorder some very
mild deficits have been found, most consistently in executive functions and
performance speed (Antila et al. 2007; Mur et al. 2007; Bearden et al. 2011;
Antila et al. 2011). In a relatively recent meta-analysis it was found that
cognitive deficits are evident in young relatives of patients with psychosis in
general (non-affective or affective), even though they might be modestly
more severe in relatives of schizophrenia patients (Bora et al. 2014).
There are several possible confounding factors in studies on
neuropsychological performance in families with schizophrenia or affective
psychosis, such as the use of different samples of relatives (for example,
parents, siblings or offspring) (Egan et al. 2001), including siblings with non-
psychotic illnesses of schizophrenia spectrum (Snitz et al. 2006) or groups of
relatives with mean age under the average risk for psychosis (Heydebrand,
2006). In addition, sensitivity of the neuropsychological methods used in
studies may vary, explaining some inconsistency in results (Trandafir et al.
2006).
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1.6.4 Shared genetic aetiology between cognition and schizophrenia
When studying subjects with a familial susceptibility to psychosis, there are
several confounding factors to the effects of shared genetic features of
patients and their relatives. Rearing environment in families with
schizophrenia may not be optimal. Offspring of parents with a psychotic
disorder may be more exposed to stress and inadequate parental care
(Walder et al. 2014; Campbell et al. 2018) as well as socioeconomic
difficulties (Howard et al. 2004) than in families without a psychotic
disorder.
   Recently, with advances in genetic technology and analytic approaches,
it  has  been  possible  to  study  the  extent  to  which  cognitive  ability  and
schizophrenia share genetic aetiology in subjects with common genetic
variants associated with schizophrenia (Hubbard et al. 2016). The proportion
of phenotypic correlation between cognition and schizophrenia due to shared
genetic  effects  has  even  been  found  to  be  21-56%  in  some  twin  studies
(Toulopoulou et al. 2007; Toulopoulou et al. 2010), but in a population-
based  twin  study  only  7%  of  the  genetic  variance  for  psychosis  was  shared
with cognition (Fowler et al. 2012). In population samples, increased
polygenic risk score of schizophrenia has been found to be weakly associated
with lower general cognitive ability (McIntosh et al. 2013; Lencz et al. 2014).
In  an  Icelandic  study  of  a  large  genotyped  sample  of  CNV  control  carriers
(subjects with CNVs but without manifest disease), cognitive performance of
carriers was found to be at a level between that of schizophrenia patients and
of population controls who were not carriers (Stefansson et al. 2014). Since
CNVs  are  not  fully  penetrant  to  the  disease  their  effect  on  cognition  of  the
carriers can be studied separately from that of the manifest disease.
1.6.5 Anhedonia and cognitive dysfunction in schizophrenia
Negative symptoms, anhedonia among them, have been found to associate
with deficits in a variety of cognitive domains in schizophrenia (Szendi et al.
2006; Winograd-Gurvich et al. 2006). In a meta-analysis on cognitive
functioning in schizophrenia, schizoaffective disorder and affective
psychosis,  people  with  schizophrenia  performed  worse  than  those  with
schizoaffective disorder or affective psychosis, but the effect sizes were small
and with substantial heterogeneity of distribution (Bora et al. 2009b). More
severe deficits in memory, psychomotor speed and executive function were
associated with greater severity of negative symptoms in schizophrenia
subjects (Bora et al. 2009b).
    Anhedonia itself has been found to correlate significantly with
generalized cognitive dysfunction in schizophrenia patients and moderate
relationships between anhedonia and measures of executive functioning and
visual memory functions have been found both among schizophrenia
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patients and their unaffected relatives (Franke et al. 1994; Laurent et al.
2000).  Particularly  physical  anhedonia  has  been  found  to  correlate  with
cognitive functioning in subjects with psychotic disorders (Brosey and
Woodward, 2015).
    In a community sample of young subjects, those with elevated social
anhedonia have been found to perform poorer than controls in tasks
measuring visual memory and visual-spatial construction (Cohen et al.
2006). Additionally, higher levels of anhedonia have been found to be related
to deficits in emotion perception in both subjects with schizophrenia and
controls (Herbener et al. 2008).
1.6.6 Cognitive deficits in subjects with PLEs.
Neuropsychological functioning in subjects with PLEs has mostly been
studied within clinical settings in young or adolescent subjects in Clinical
High Risk (CHR) studies. In CHR subjects, psychotic-like symptoms have
been associated with lower working memory capacity (Ziermans, 2013) as
well as with impaired performance in a visuospatial task (Lindgren et al.
2010). Neuropsychological deficits have been found to predict psychosis in
several  CHR  samples  (Keefe  et  al,  2006;  Wood  et  al,  2007;  Cannon  et  al.
2016). In a follow-up study, those CHR subjects who progressed to psychosis
had more severe cognitive deficits, while those at-risk subjects who did not
convert  to  psychosis  did  not  differ  significantly  from  controls  (Keefe  et  al,
2006). In a recent large multicentre study, high-risk subjects were found to
have deficits in attention, working memory and declarative memory, with
most severe deficits in subjects who later developed psychosis (Seidman et al.
2016). In a study from North American Prodrome Longitudinal Study on
predictors  for  psychosis  in  CHR  subjects,  higher  levels  of  unusual  thought
content and suspiciousness, greater decline in social functioning, lower
verbal learning and memory performance, slower speed of processing and
younger  age  at  baseline  each  contributed  to  individual  risk  for  psychosis
(Cannon et al. 2016).
   It has been suggested that the effects of genetic risk and clinical status
on  cognitive  function  are  independent  in  CHR  subjects,  and  that  cognitive
deficits associated with early psychosis are genetically mediated and can
occur in genetically vulnerable individuals regardless of their clinical status
(Myles-Worsley et al, 2007). In a recent meta-analysis on young subjects
(mean  age  from  15  to  29),  it  was  found  that  co-occurrence  of  both  familial
and clinical risk associated with more severe cognitive dysfunction (Bora et
al.  2014).  In  the  same  study,  it  was  also  found  that  the  CHR  subjects  who
developed psychotic disorders at follow-up had more severe cognitive deficits
at baseline with effect sizes varying (between d=0.31-0.49) on all cognitive
domains except sustained attention. There was a significant overlap of
baseline cognitive performance of the clinical high-risk subjects who did or
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did not develop psychosis. Hence, cognitive deficits may have only a limited
capacity to predict the outcome of high-risk patients (Bora et al. 2014).
   Outside clinical settings with help-seeking subjects, research is scarce.
The available studies with non-help-seeking CHR individuals suggest that
they  have  less  cognitive  deficits  (Mukkala  et  al.  2011).  Older  subjects  with
PLEs have not been thoroughly studied possibly because they are above the
risk age for conversion to psychosis (Fusar-Poli et al. 2014).
1.7 Motivation for the current studies
Middle-aged subjects with vulnerability to psychosis have received less
attention than adolescents or young adults, understandably since psychotic
disorders most often develop at young age. However, considering the
importance of understanding risk features for psychosis and their
manifestation in different age groups, after average risk age of onset of a
psychotic disorder, exploring older subjects with presumable risk to
psychosis is relevant. The present thesis focuses on two adult populations
with either familial or clinical risk for psychosis. Cognitive functioning in
these  groups  is  explored,  as  well  as  whether  psychotic-like  symptoms  in
middle-aged subjects predict future psychosis. The aim is to have more
understanding on the way cognitive functioning and clinical symptoms
relating to vulnerability to psychotic illness manifest in these populations.
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2 AIMS OF THE PRESENT STUDIES
The present thesis focuses on two middle-aged populations who presumably
have a higher risk for psychotic disorders than the general population:
1) siblings of patients with schizophrenia
2) adults with psychotic-like symptoms
The specific aims of the study were:
I) To explore differences in cognitive performance between healthy
siblings of schizophrenia patients and a representative,
population-based control group (Study I)
II) To find out whether levels of social and physical anhedonia differ
between subjects with schizophrenia spectrum disorders and their
unaffected siblings with a population-based control group and to
explore associations of physical and social anhedonia with
cognitive performance (Study II)
III)  To explore cognitive performance and psychosocial functioning of
subjects with psychotic-like or manic-like experiences (PLEs or
MLEs) in comparison with control subjects in a sample of middle-
aged adults from a general population survey (Study III)
IV) To study, using the same population-based sample as in Study III,
whether PLEs, MLEs or cognitive performance at baseline predict




3.1 Two population samples
Samples for studies in this thesis were drawn from two large population-
based samples of subjects, with a focus on subjects with different
vulnerability features relating to possible susceptibility to psychosis and
population controls without such features. Studies I and II are based on a
large sample of families with at least two siblings with schizophrenia and
their first-degree relatives from Finland, with control subjects from the
Health 2000 study, a representative national health examination survey.
Studies III and IV are based on the Health 2000 Study sample, with Study IV
also including data from the Health 2011 study, which is a follow-up study of
the Health 2000 study sample.
3.1.1 Schizophrenia family data
A large population-based sample of families with schizophrenia was recruited
for  studying  the  genetic  epidemiology  and  molecular  genetics  of
schizophrenia from the beginning of 1990. Data from three nationwide
computerized health care registers (Medication Reimbursement Register,
Hospital Discharge Register and Pension Register) was used to identify from
the Finnish population all persons born from 1940 to 1976 who had received
a diagnosis of schizophrenia, schizophreniform disorder or schizoaffective
disorder (n=33731). After the patients had been identified, the National
Population  Register  was  used  to  link  the  patients  to  their  first-degree
relatives. The study protocol was accepted by the Ethics Committee of the
National Public Health Institute and the Hospital District of Helsinki and
Uusimaa, and the study was approved by the Ministry of Social Affairs and
Health of Finland. Each affected subject was only contacted after having
permission from the treating physician, and remaining family members
contacted after the affected subject had given consent. All study subjects gave
written informed consent for the study protocol.
    From the identified families, two samples assumed to have a high
genetic risk for schizophrenia were selected, one of which was a nationwide
sample of randomly selected 643 families with at least two or more siblings
with a diagnosis of schizophrenia, schizoaffective disorder or
schizophreniform disorder and at least two siblings with no psychiatric
diagnosis. This nationwide sample was used in the Studies of the current
thesis.
From the aforementioned 643 families a subsample was randomly selected in
order to collect more detailed phenotypic information. For this sample a
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psychiatric interview using the Clinician Version of the SCID interview for
DSM-IV (SCID-I for Axis I disorders and SCID-II for Axis II disorders, First
et al., 1997), neuropsychological assessment and several rating scales were
conducted. The interviewers were psychiatrists, psychologists or advanced
psychiatric  nurses  who  were  trained  and  supervised  in  the  use  of  these
instruments. Case records were collected for hospital and outpatient
treatment for mental disorders. The lifetime diagnosis for each patient was
assessed by two psychiatrists according to the Diagnostic and Statistical
Manual  of  Mental  Disorders  (DSM-IV,  1994),  independently  of  each  other.
The Operational Criteria Checklist for Psychotic Illness OPCRIT (McGuffin et
al., 1991) was also filled by one of the assessors. In case of disagreement, the
diagnosis was also assessed by a third psychiatrist, and a consensus diagnosis
was established. All available medical records, the OPCRIT process and the
SCID interview were used when assessing the final consensus diagnosis.
Altogether, 305 subjects from 63 families were collected. All families in the
sample represented familial schizophrenia. In each of the families there was
at least one sibling with a diagnosis of schizophrenia, plus at least one other
sibling with schizophrenia, schizoaffective disorder or schizophreniform
disorder (Hoti et al., 2004).
3.1.2 The Health 2000 Survey and the Psychosis in Finland
The Health 2000 study is a Finnish general population health survey of a
nationally representative two-stage cluster adult sample of 8028 persons
aged  thirty  or  over  (https://thl.fi/fi/tutkimus-ja-kehittaminen/tutkimukset-ja-
hankkeet/terveys-2000-2011). Additionally, a young adult cohort including 1894
subjects aged 18-29 years in the year 2000 was collected (Koskinen et al.,
2005). The Health 2000 baseline study took place between September 2000
and June 2001. It consisted of a home interview and a health examination at
the local health centre, or a condensed interview and health examination at
home or institution for those unable to attend in the healthcare centre. A
telephone interview or a mail questionnaire was arranged for remaining
subjects. Register information was gathered for the whole sample in order to
complement baseline information and for follow-up purposes. The Hospital
District of Helsinki and Uusimaa approved of the study design, and written
informed consent was obtained from the participants.
    The health examination of the Health 2000 study included a shortened
version  of  the  Münich-Composite  International  Diagnostic  Interview  or  M-
CIDI (Wittchen et al. 1998). The interview included the sections on
depression, mania, anxiety, psychotic symptoms and substance use.
However, M-CIDI alone is not a reliable instrument for diagnosing psychotic
disorders (Kendler et al. 1996). Hence, the Psychoses in Finland (PIF) study,
a substudy of the Health 2000 focusing on epidemiology of psychotic
disorders in Finland, was conducted. The whole baseline adult sample of the
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Health 2000 survey was screened for possible psychotic disorders with a so-
called  PIF  Screen  (Perälä,  2007)  consisting  of  several  elements,  outlined  in
Figure 1.  Items from the M- CIDI interview that were utilized in the screen
are presented in Table 4.
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1 Between 1996-2002
2 the Munich Composite International Diagnostic Interview












Section F for bipolar disorder











Section P for formal thought disorder,
negative and catatonic symptoms









for free outpatient antipsychotic medication
(severe psychotic or other mental disorder)
Pension Register for a disability
pension because of psychotic, bipolar or
major depressive disorder
Prescription Register lithium or mood
stabilizing anticonvulsant use1 without a
diagnosis of epilepsy/other neurological
disorder
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Table 4. TheM-CIDI1 sections
Section F screen for
bipolar disorder
Positive if a subject had had a lifetime episode of elevated or irritable
mood  lasting  at  least  four  days  and  had  at  least  three  out  of  twelve
manic-like symptoms in the CIDI. The symptoms did not have to be
concurrent with the elevated or irritable mood




Positive if a subject had experienced any of the 22 psychotic-like
symptoms probed in the CIDI, if the symptom had had clinical
relevance (had interfered with normal life or if the subject had talked
about them to a healthcare professional), or a subject reported three or
more symptoms regardless of clinical relevance




Positive if during the CIDI interview, as assessed by the interviewer
there were symptoms of positive formal thought disorder, negative
symptoms, behaviour suggesting the subject is having hallucinations or
catatonic symptoms
Remark section and the
screen for odd
behaviour
The interviewer noted remarks concerning the individual and the
interview. If a subject was not selected by any other screen, but these
remarks were indicative of a psychotic disorder, the screen was positive
1 the Münich Composite International Diagnostic Interview
If any of the screening elements were positive, the subject was invited for a
re-interview (n=746). The re-interview consisted of the Structured Clinical
Interview for DSM-IV Axis I Disorders (SCID-I) (First et al. 1997),
neuropsychological assessment and several rating scales. Hospital and
outpatient case notes from psychiatric and primary care units from all
lifetime treatment contacts for all mental health problems of the subjects
were also collected, with the approval of the Finnish Ministry of Social Affairs
and Health. Final diagnoses were based on a consensus between interviewer
and clinical supervisor using data from the SCID-I interview and medical
records from possible mental health treatment. The current study included a
group of subjects who had psychotic- or manic-like experiences based on the
CIDI,  but  who  did  not  get  a  diagnosis  of  a  psychotic  disorder  with  the
thorough diagnostic procedure during the PIF study (n=430).
A sample of subjects comprising the group of population controls was also
randomly selected from participants of the Health 2000 study (n=174). Of
the selected controls, 24 were selected by the PIF screen and not used as part
of the control group for these analyses. These selected 150 controls were also
invited for a re-interview, and 114 persons were assessed with psychiatric and
neuropsychological methods also included in the family sample study
described above.
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3.1.3 The Health 2011 Survey
The  Health  2011  Survey  (https://thl.fi/fi/tutkimus-ja-kehittaminen/tutkimukset-ja-
hankkeet/terveys-2000-2011) is a follow-up study of the Health 2000 Survey. All
participants of the Health 2000 Survey who were alive and living in Finland
and  who  had  not  refused  further  contact  (Markkula  et  al.  2015;  Koskinen,
2012) were included. The survey included a general health interview, during
which sociodemographic information and psychiatric disorders diagnosed by
a physician were asked for. Psychiatric disorders at follow-up were assessed




From the 63 families with members with schizophrenia, schizoaffective or
schizophreniform disorder who were thoroughly assessed, further exclusions
were made in order to analyse neuropsychological performance between the
groups of affected subjects, their healthy siblings and control subjects from
the general population. From the patients with schizophrenia (n=105) and
their healthy relatives with no lifetime mental disorder (n=106), all parents
as well as siblings over 70 years of age were excluded (5 patients, 28 healthy
relatives).  Other  exclusion  criteria  were  lack  of  co-operation  (due  to
symptoms of schizophrenia, 14 patients), current alcohol or substance use
disorders (4 patients), and finally mental retardation or neurological
disorder (1 patient). After exclusions, the final study sample included 81
schizophrenia patients and 78 healthy siblings from 58 families. Within the
group of affected subjects, mean age of onset was 23.0 years, varying from 14
to  42  years.  Almost  all  affected  subjects  were  on  antipsychotic  medication,
often with polypharmacy. No siblings had antipsychotic medication, but one
reported benzodiazepine use.
3.2.2 Control group
From the  aforementioned  114  control  subjects  from the  Health  2000 study
adult sample, we excluded subjects with a lifetime diagnosis of any psychotic
disorder, current alcohol or substance use disorder, mental retardation or
neurological  disease,  as  well  as  subjects  who  were  70  years  or  older.  In
addition, subjects with a family history of mental disorder (assessed by self-
report at interview) were excluded. After exclusions, 55 subjects fulfilled the
inclusion  criteria.  At  this  point  the  mean  age  of  the  control  sample  was
significantly higher than that of the family sample. Hence, we randomly
selected 15 control subjects from the aforementioned Health 2000 young
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adult cohort sample (Koskinen et al, 2005). These subjects were assessed
with the same interview and neuropsychological methodology as the adult
sample, and similar inclusion requirements were applied. The final
population-based control group in Study I comprised 70 subjects.
3.3 Study II
3.3.1 Family sample
Subjects  for  Study  II  were  from the  same 63  families  as  in  Study  I,  but  for
Study  II  all  affected  subjects  with  a  schizophrenia  spectrum  psychotic
disorder were included in order to have more statistical power. In this study
we first excluded subjects who were over 70 years of age (21 relatives, 1
subject with schizophrenia), and those who were untestable for
neuropsychological assessment due to lack of co-operation or interruption in
the testing situation (3 relatives and 18 affected subjects). Further, all
parents were excluded (10 relatives, 4 affected subjects). Other exclusion
criteria were current alcohol or substance use disorders (6 affected subjects
and  10  non-psychotic  siblings),  and  mental  retardation  or  neurological
disorder (1 affected subject and 1 non-psychotic sibling). After the exclusions
the final study sample comprised 91 siblings with a schizophrenia spectrum
psychotic disorder (73 subjects with schizophrenia, 12 with schizoaffective
disorder and 6 with schizophreniform disorder) and 105 unaffected siblings
from 56 families. The affected subjects had a mean age of onset of 24.3 years
(varying from 14 to 50 years, information available for 93% of the affected
subjects). Almost all of the affected subjects were on antipsychotic
medication, often with several psychotropic drugs.
For Study II the unaffected siblings were further divided into a group of 30
siblings with non-psychotic psychiatric disorders, and a group of 75 siblings
without any psychiatric disorder. Among those with non-psychotic
psychiatric disorders there were 12 persons with anxiety disorder, 7 with
depressive disorder and 7 with a diagnosis of lifetime substance use disorder.
Three subjects had comorbid depressive and anxiety disorder, and one
person had comorbid depressive and eating disorder as well as dependent
personality disorder. The study diagnoses were based on SCID interviews
complemented by case notes when available. Of the siblings with non-
psychotic psychiatric disorders, 3 reported using antidepressants, 2 using
sedatives and one using both an antidepressant and a sedative.
3.3.2 Control group
The  same  control  group  as  in  Study  I  was  used  as  a  basis  for  the  control
group  in  Study  II.  For  Study  II  the  subjects  who  had  not  filled  in  the
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Chapman anhedonia scales (which were used in the study) were excluded,
hence the control group consisted of 67 subjects.
3.4 Studies III and IV
For Studies III and IV, psychotic-like or manic-like experiences reported in
the CIDI during the PIF screening procedure described earlier were used as
inclusion criteria (see Table 3 for more detail on the CIDI sections for PLEs
and MLEs). Altogether 430 PIF subjects with a possible psychotic disorder
had valid data from both the aforementioned SCID I interview and the CIDI.
For Studies III and IV the control group comprised only the Health 2000
study adult sample (the aforementioned 114 subjects from the Health 2000
adult sample before exclusions), because there were no significant
differences between mean ages of study groups in Studies III and IV.
3.4.1 Baseline (Study III)
Exclusion criteria for baseline (Study III) are presented in Figure 2. Of note,
people who in the CIDI interview reported that PLEs or MLEs had been due
to alcohol/substance use were also meant to be excluded, but there were no
such subjects left after other exclusions. After exclusions, the groups of
subjects  with  PLEs  (n=90)  and  MLEs  (n=52)  were  formed.  From  the  114
control subjects with no psychotic symptoms in the PIF Screen and valid data
from the CIDI as well as from neuropsychological assessment, there
remained 66 subjects after exclusions. For controls, family history of
psychotic disorders was asked for during the interview.
51
Figure 2. Exclusion criteria for baseline in Study III
Samples with valid data from re-interview and the CIDI at
Health 2000 baseline
Study sample n = 430 Control group n = 114
Exclusion criteria:
Age over 70 years n = 84
Affected subjects (with psychotic disorder) n = 198
Control subjects with a positive CIDI screen n = 4
Subjects with no findings in CIDI but self-reported
psychotic symptoms n = 2
Neurological disease n = 4
Developmental cognitive dysfunction n = 1
Visual disability n = 1
Mother tongue not Finnish n = 7
Testing interrupted due to medical condition n = 1
Study sample divided
based on the CIDI:
PLEs (with psychotic-like
experiences) n = 102
MLEs (with manic-like
experiences) n = 60
Control group n = 80
Final exclusions:
Current substance use disorder (PLE n = 6, MLE n = 7, control n = 6)
Current depressive disorder (PLE n = 6, MLE n = 1, control n = 3)
For controls: family history of psychotic disorder (n = 5)
Study groups at baseline:
PLEs n = 90
MLEs n = 52
controls n = 66
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3.4.2 Follow-up (Study IV)
Data for follow-up came from two sources. First, interview data was obtained
for those baseline subjects who were alive and participating in the Health
2011 Survey. This included subjects with psychotic-like experiences (PLEs) at
baseline (n=86), subjects with manic-like experiences (MLEs) at baseline
(n=45) and control subjects (n=62).
Second, register data on hospitalizations for psychiatric disorders,
dementia, suicide attempt or death during follow-up period (2000-2011) was
obtained for all study subjects (subjects with PLEs n=90, subjects with MLEs
n=52 and controls n=66). This information was also obtained for those
subjects who had died during the follow-up or refused to participate. The
information was gathered from the Care Register for Health Care (HILMO,
former national hospital discharge register) managed by the National
Institute for Health and Welfare. It covers all public and private hospitals in
Finland for hospitalizations. Also, information of free outpatient
antipsychotic medication, for severe psychotic or other severe mental
disorders, from the Medical Reimbursement Register of the Finnish Social
Insurance Institution was obtained for all of the baseline subjects.
3.5 Neuropsychological assessment
Neuropsychological assessment consisted of internationally used and
validated tests. The selected test battery was presented to all study subjects in
a fixed order. Examiners were extensively trained and supervised in the use
of the tests. The tests were scored following standardized procedures. The
following cognitive domains were assessed.
General ability was measured with the Vocabulary subtest of the Wechsler
Adult Intelligence Test–Revised (WAIS-R) (Wechsler, 1981). The test reflects
verbal concept formation. It is usually well preserved in different
neurological  conditions  and  is  considered  to  be  the  best  single  measure  of
general ability and premorbid intellectual functioning (Lezak et al. 2004).
Visual-motor performance was measured with the Digit Symbol task of the
WAIS-R. It is a task reflecting a multitude of performance efficiency
functions such as processing speed, response-orientation and search for an
appropriate code (Andrewes, 2016).
Simple  auditory  attention  was  measured  with  the  Digit  Span  Forward
subtest of the Wechsler Memory Scale–Revised (WMS-R) (Wechsler, 1987).
Verbal working memory was assessed with the Digit Span Backward subtest
of the WMS-R.
Simple visual attention was measured with the Visual Span Forward
subtest and visual working memory with the Visual Span Backward subtest
of the WMS-R.
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Several variables from the California Verbal Learning Test (CVLT) (Delis
et al, 1987) were used to measure verbal learning and memory. In the CVLT
the  examinee  is  required  to  learn  a  16-item word  list  over  five  trials  and  to
recall/recognize items on the list after a short and longer (approximately 20
minutes) delay. It yields several parameters that can be used as independent
variables. The verbal memory variables included in all of studies (Studies I-
IV) were:
1) Total  recall  from trials  1-5  as  the  variable  for  learning,  which  is  the
number of words recalled during all five trials.
2) The semantic clustering score for learning strategy. The score
indicates the use of a learning strategy during learning task in order
to reorganize words of the list into categorical groups.
3) The short delay recall was used as a measure for immediate recall of
the material learned after five trials.
4) The long delay recall was used as a measure for delayed recall of the
material learned after five trials.
In addition to these variables of  the CVLT, in Study I  the learning slope
index was used to measure increase in recalled words per trial, and the recall
errors indices (perseverative and intrusion errors) were used to measure
repetition and intrusive errors during the task. In Study I, the cued versions
of the short and long delay recall tasks were also used.
The efficiency of visual scanning, attention and mental flexibility were
assessed with parts A and B of the Trail Making Test (TMT) (Reitan and
Wolfson, 1993). Part A (TMT A) is a measure of simple visual-spatial
attention and performance speed, whereas part B (TMT B) also requires
executive functions (ability to shift attention and strategy) and visual
working  memory  (Lezak  et  al,  2004).  Performance  time  was  used  in  the
analyses,  and  possible  errors  made  by  the  examinee  were  not  corrected  by
the examiner. In Study I the difference score B-A, that diminishes the effect
of the speed component and emphasizes the executive aspect of the task
(Lezak et al, 2012), was also used.
Raw scores were used in all Studies and the performance of the study
groups was compared to that of control subjects. Higher scores indicated
better performance in all tests, except in the TMT and in the perseverative
and intrusive errors of the CVLT.
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3.6 Rating scales and questionnaires used
3.6.1 Schizophrenia family data
In  Study  II,  anhedonia  was  measured  with  two  of  the  Chapman  Psychosis-
Proneness scales, the Revised Social Anhedonia Scale (RSAS) (Mishlove et al,
1985) and Physical Anhedonia Scale (PAS) (Chapman et al, 1976). They are
true/false questionnaires developed to measure individual differences in the
capacity to experience pleasure from social/interpersonal and
physical/sensual sources (Horan et al, 2006). The RSAS has 40 and the PAS
60 items and the sum of these two sets of items were used as the variables for
social  and  physical  anhedonia  in  Study  II.  The  original  English  versions  of
the scales were translated into Finnish and back-translated blindly into
English by a professional English translator, after which the original versions
and the back-translated version were compared and corrections made
accordingly (Miettunen et al, 2010).
3.6.2 Psychosis in Finland and control data
The Finnish versions of the following rating scales and questionnaires were
used in the Health 2000 Study and hence available for Study III: Global
Assessment  of  Functioning  (GAF)  (Ramirez  et  al.  2008)  for  current
psychosocial functioning, Social and Occupational Functioning Assessment
Scale (SOFAS) (Goldman et al. 1992) for current social and occupational
functioning and Beck Depression Inventory (BDI) (Beck et al. 1961) for
current depressive symptoms. The GAF was evaluated as a part of the
interview,  as  instructed  in  the  DSM-IV  (APA,  2000).  In  the  Health  2011
follow-up survey there were some changes in the measures used (due to
economic and time constraints). Hence the General Health Questionnaire
(GHQ-12) was used for screening current psychological distress (Goldberg,
1972) and the thirteen-item version of the Beck Depression Inventory (BDI-
13; Beck and Beck, 1972) for current depressive symptoms. The 13-item
version has been shown to perform equally well previously (Aalto et al. 2012).
3.7 Statistical methods
3.7.1 Statistical methods for Study I
A generalized estimating equation (GEE) model that estimates population-
averaged regression coefficients (Zeger, 1986) was used for comparison of
neuropsychological test performance between groups of schizophrenia
patients, healthy siblings and controls. This model was used to control for
family correlation as the data was derived from families and thus could not
be considered independent. Statistical models were adjusted for age, gender
and education, since all of them may have had a modifying effect on cognitive
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functioning (Lezak et al, 2004). The analyses were carried out with the Stata
statistical  software,  version  8.2  (StataCorp,  2003).  The  type  I  error  was
controlled for by Bonferroni correction and p<.002 was considered
significant, while p<.05 but >.002 were considered indicative of significance.
Effect sizes (d) were also calculated (Cohen, 1988).
3.7.2 Statistical methods for Study II
The internal consistency of responses for social and physical anhedonia was
calculated with Cronbach . Comparison of anhedonia scores between
groups of subjects with schizophrenia spectrum disorders, unaffected
siblings with non-psychotic disorders, unaffected siblings without non-
psychotic disorders and controls were carried out with a similar GEE model
that estimated population-averaged regression coefficients (Zeger, 1986) in
Study  I,  in  order  to  control  for  the  family  correlation.  All  models  were  also
adjusted for gender, since gender differences in reported anhedonia levels
are common (Erlenmeyer-Kimling et al, 1993; Miettunen et al, 2010). These
statistical analyses were carried out using the Stata statistical software,
version 9.0 (StataCorp, 2005).
Random effects model was used to investigate independent effects of
social and physical anhedonia, group membership (schizophrenia spectrum
disorders, unaffected siblings and controls), age, education and gender on
neuropsychological variables. In these analyses, family membership was used
as a random effect to control for the within-family correlation. The Wald test
was used to calculate group status x social/physical anhedonia interactions
on neuropsychological variables.
Differences in neuropsychological performance between unaffected
siblings with and without non-psychotic disorders, as well as between the
siblings with non-psychotic disorders and controls were also analysed with a
similar  GEE  model  as  in  comparisons  of  anhedonia  scores.  These  analyses
were adjusted for age, gender and education, since all of them have a
modifying effect on cognitive function (Lezak et al, 2004). Finally, a random
effects model described above was used to investigate the effects social and
physical anhedonia, group membership, age, education and gender on
neuropsychological variables with both social and physical anhedonia as
predictors in the same model. Also, in Study II the type I error was controlled
for with the Bonferroni correction and p values <.004 were considered
significant.
3.7.3 Statistical methods for Study III
SPSS software version 21.0 was used in the analyses for Study III. Pearson’s
Chi-Square test was used to compare differences between groups in gender,
education level (as a categorical variable basic, secondary or high) and
lifetime non-psychotic psychiatric diagnoses (yes or no). Differences in
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continuous  variables  (age,  GAF,  SOFAS and  BDI  scores)  between  the  study
groups were explored with one-way analysis of variance (ANOVA).
The differences in neuropsychological performance between the study and
control groups were analysed with linear regression modelling. These were
conducted  separately  between  each  study  group  and  the  control  group  and
also between all of the study groups. Age and gender were used as covariates.
As education level did not differ between groups, it was not included in these
between-group analyses.
3.7.4 Statistical methods for Study IV
SPSS software version 23 (IBM Statistical Software, IBM Corp.) was used for
the analyses. Differences between groups of subjects with PLEs, MLEs and
controls in gender, self-reported health status (good or rather good on a
Likert scale), family status and employment status were calculated with the
Pearson’s Chi-Square Test. One-way ANOVA was used to calculate
differences in age, BDI-13 and GHQ-12 scores. For analysis on baseline
variables predicting psychiatric condition at follow-up a binary logistic
regression model was used. For these analyses a variable “any psychiatric
disorder during follow-up” that combined information from HILMO register,
interview data and the CIDI was formed. This was done in order to have
more statistical power in analyses. In the case of a subject having information
of psychiatric disorders from several sources, register information was
considered first, then information from interview and the CIDI so that each
subject was represented as one case with/without diagnosis.
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4 RESULTS
4.1 Cognitive performance of schizophrenia patients, healthy
siblings and population controls (Study I)
Demographic characteristics of the study groups and mean and standard
deviations of cognitive variables within each group and between-group
comparisons are presented in Tables 5 and 6. The groups differed regarding
age and education: the affected subjects were slightly younger and had a
lower  education  level  than  the  other  groups  (with p values .01 and .0001,
respectively).
Table 5. Mean and standard deviations of demographic characteristics in












42 / 39 39 / 39 35 / 35 .95a
Mean    SD Mean SD Mean  SD
Age 44.5   7.3 48.8 9.5 46.6 13.0 .01b
Education
(years)







a models adjusted by age, education and gender
The main differences between healthy siblings and control subjects were
found in neuropsychological tasks requiring performance speed and
executive functions (Table 6). Siblings were significantly slower both in
visual-motor  and  performance  speed  (measured  with  the  Digit  Symbol
subtest of the WAIS-R, p<.0001,  and  the  TMT  A, p<.0001) than controls.
Also,  in  tasks  with  an  executive  component  (the  TMT B and  TMT B-A)  the
Table 6. Mean and standard deviations of neuropsychological variables and comparison between groups
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Mean SD Mean SD Mean SD p p p
Vocabulary1 28.1 13.3 40.8 11 41.9 10.4 <.0001 <.0001 .18
Digit span
forward2
5.9 1.9 6.9 1.9 7.7 1.9 <.0001 <.0001 .12
Digit span
backward2
4.6 1.7 5.9 2.3 6.4 1.9 <.0001 <.0001 .54
Visual span
forward2
7.3 1.8 9.0 2.0 8.5 2.0 <.0001 <.0001 .13
Visual span
backward2
6.2 2.4 8.2 1.8 8.2 1.8 <.0001 <.0001 .83
Total recall3 31.9 12.0 45.0 10.6 49.7 9.8 <.0001 <.0001 .06
Learning slope3 0.8 0.5 1.14 0.56 1.4 0.6 <.0001 <.0001 .07
Semantic
categories3
6.2 4.9 11.6 6.8 15.7 9.0 <.0001 <.0001 .02
Intrusions3 7.2 13.4 4.9 5.7 2.4 3.4 .79 <.0001 .01
Perseverations3 3.9 6.1 6.5 2.7 4.3 4.5 .15 .78 .10
Immediate recall,
free3
6.7 3.3 9.4 2.7 10.7 3.1 <.0001 <.0001 .05
Immediate recall,
cued3
8.0 2.9 10.5 2.6 11.7 2.6 <.0001 <.0001 .03
Delayed recall,
free3
7.2 3.4 10.2 2.6 11.3 3.2 <.0001 <.0001 .13
Delayed recall,
cued3
7.8 3.4 10.6 2.5 11.8 2.8 <.0001 <.0001 .12
Trail Making
Test A
67.8 31.4 44.5 24.6 32.2 13.2 <.0001 <.0001 <.0001
Trail Making
Test B
166.6 84.7 119.7 64.0 83.0 40.7 <.0001 <.0001 <.0001
Trail Making
Test B-A
102.3 66.4 77.7 54.5 50.8 36.7 .014 <.0001 .001
WAIS-R Digit
symbol1
28.9 10.6 43.1 13.9 52.8 15.0 <.0001 <.0001 <.0001
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siblings  were  slower  than  controls,  with p values <.0001 and .001,
respectively.
With the Bonferroni correction used in Study I, there were no more
significant differences between siblings and controls. In these comparisons
the effect sizes calculated were from small to moderate. The highest of those
(d=0.58-0.68) were for measures of performance speed and executive
functions (TMT A, B and B-A as well as the Digit Symbol test), and also with
d varying between 0.51-0.59 for some of the verbal memory measures used
(using semantic categories as a learning strategy and making intrusive or
perseverative errors during recall).
When comparing the affected subjects with schizophrenia and control
subjects, the performance of the former group was significantly poorer in all
neuropsychological measures used. In comparisons between the affected
subjects and healthy siblings, the affected subjects still had poorer
performance in almost all neuropsychological measures used, with an
exception in the amount of perseverative or intrusive recall errors. The effect
sizes calculated were mostly from moderate to large indicating a manifest
cognitive dysfunction in the patient group.
4.2 Anhedonia and cognition in subjects with schizophrenia
spectrum disorders, non-psychotic siblings and population
controls (Study II)
Subjects with schizophrenia spectrum psychotic disorders had significantly
higher  levels  of  social  and  physical  anhedonia  than  the  siblings  with  or
without non-psychotic psychiatric disorders or controls (with p values .001,
<.0001 and <.0001, respectively). There were no differences in levels of
social or physical anhedonia between groups of siblings with or without non-
psychotic psychiatric disorders and controls. Cognitive performance of
siblings with and without non-psychotic psychiatric disorders did not differ.
In separate random effects models for predictors of performance on each
neuropsychological variable, physical or social anhedonia, age, gender,
education and the effect of having a schizophrenia spectrum disorder or
having familial vulnerability (siblings from families with schizophrenia) were
included as predictors. Family membership was used as a random effect to
control for the within-family correlation. In the first model with physical
anhedonia, higher physical anhedonia associated with poorer performance in
several variables of the CVLT used to measure verbal learning and memory.
Coefficients  for  the  effect  of  increase  in  scores  of  physical  anhedonia  were:
effect coefficient =-0.28, p=.001 for CVLT total recall, effect coefficient =-
0.16, p=.003 for semantic clustering and effect coefficient =-0.06, p=.004 for
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delayed recall. Additionally, higher physical anhedonia associated with lower
performance in concept formation as measured with the WAIS-R Vocabulary
subtest (effect coefficient=-0.30, p=.0001). Having a schizophrenia spectrum
disorder associated significantly with poor performance in all cognitive
domains  assessed  here.  Being  a  sibling  from  a  family  with  schizophrenia
associated with slower performance in the Digit Symbol subtest of the WAIS-
R (effect coefficient=-5.48, p=.001) but not with other cognitive variables. In
a second model with social anhedonia as one of the predictors, social
anhedonia was not associated with performance in any of the
neuropsychological measures. In this model with social anhedonia, having a
schizophrenia spectrum disorder was significantly associated with poor
performance in all neuropsychological domains explored in this study. Being
a sibling from a family with schizophrenia associated with slower
performance in the Digit Symbol test (effect coefficient=-5.58, p=.001).
4.3 Psychosocial and cognitive characteristics of subjects
with psychotic-like or manic-like experiences (Study III)
There were differences in sociodemographic and clinical characteristics
between  the  PLE  group,  the  MLE  group  and  controls.  Subjects  with  MLEs
were less often married or cohabiting, had more lifetime non-psychotic
psychiatric diagnoses as well as more psychiatric comorbidity than controls
or subjects with PLEs.  The characteristics of the study groups are presented
in Table 7.
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Table 7. Demographic characteristics of controls, subjects with psychotic-like experiences and
subjects with manic-like experiences
Controls n = 66 Subjects with
psychotic-like
experiences n = 90
   Subjects with
    manic-like
experiences n = 52
p
Mean SD Mean SD Mean SD
Age 50.6 10.1 49.5 10.3 46.8 9.5 .12a
Gender
(M/F)




Basic 32 23 25
Secondary 36 33 33
High 32 39 33
Current
employment1
Full/part-time 63.5 72 79
Married/
cohabiting





39 34 62      .003b,2
a One-way ANOVA, p < .05 was considered significant
bChi2, p < .05 was considered significant
1Education level was classified as basic (comprehensive school or equal), secondary (occupational school/upper secondary
school) and high (university degree or similar), classification designed for the T2000 Health Survey (Aromaa & Koskinen,
2004)
2In additional analyses, the subjects with MLEs had significantly more lifetime non-psychotic diagnoses than the controls (p =
.01) or the subjects with PLEs (p. = 001)
In general, differences between groups in neuropsychological variables, the
BDI, the GAF and the SOFAS scores, were small (see Table 8). The subjects
with MLEs had significantly higher scores in the BDI (p=.04), and
significantly lower scores in the GAF (p=.02) than the controls. The subjects
with PLEs only had significantly lower scores than controls in the GAF
(p=.02). The subjects with PLEs were slightly, but significantly, slower than
controls  in  the  TMT  A  ( =0.149, p=.04), and subjects with MLEs slightly
slower  than  controls  in  the  Digit  Symbol  subtest  of  the  WAIS-R ( =-0.146,
p=.04), but no other significant differences in cognitive performance were
found.
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Table 8. Mean and standard deviations and between-group comparisons of neuropsychological





























Mean (SD) Mean (SD) Mean (SD) p p p
Vocabulary1 42.1 (10.3) 42.1 (10.8) 40.2 (10.7) .94 .17 .16
Digit span
forward2
7.3 (1.8) 7.4 (2.3) 7.2 (2.2) .85 .33 .34
Digit span
backward2
6.0 (1.7) 6.0 (1.7) 6.0 (1.6) .90 .48 .33
Visual span
forward2
7.9 (1.7) 8.2 (1.8) 8.4 (2.1) .51 .88 .99
Visual span
backward2
7.8 (1.8) 8.0 (2.1) 8.1 (1.8) .85 .97 .89
Total recall3 47.8 (10.8) 51.1 (10.1) 51.8 (11.9) .09 .25 .89
Semantic
categories3
15.2 (9.8) 17.6 (10.2) 18.5 (13.2) .14 .37 .75
Immediate
recall3
10.4 (3.5) 11.2 (2.8) 11.2 (3.1) .17 .75 .49
Delayed recall3 10.7 (3.6) 11.7 (2.8) 11.7 (3.2) .06 .51 .46
TMT A 33.3 (12.9) 36.6 (17.1) 33.6 (10.5) .04 .12 .93
TMT B 88.5 (43.8) 91.3 (48.2) 83.2 (32.3) .21 .54 .69
Digit Symbol1 50.0 (14.8) 50.3 (14.3) 50.3 (13.9) .28 .04 .20
BDI 4.8 (5.0) 6.0 (4.4) 7.3 (8.1) .12 .04 .23
SOFAS 83.3 (9.2) 80.4 (10.9) 81.0 (8.5) .08 .17 .75
GAF 82.9 (9.4) 79.0 (10.8) 78.8 (9.2) .02 .02 .90
Abbreviations: TMT, the Trail Making Test, BDI, The Beck Depression Inventory, SOFAS, the Social and Occupational




a linear regression analyses with age and gender as covariates, p < .05 was considered significant
b One-way ANOVA, p < .05 was considered significant
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4.4 Associations of psychotic-like or manic-like experiences
with later psychiatric disorders: an 11-year follow-up (Study
IV)
Characteristics of the study groups at follow-up are presented in Table 9.
There  were  more  deaths  during  the  follow-up  period  in  the  MLE  group
(11.5%)  than  in  other  groups  (PLE  group  3.3%  and  controls  4.5%)  but
otherwise loss to follow-up of study subjects was fairly low. Groups did not
differ significantly in self-reported health status, marital or employment
status at follow-up. The severity of reported depressive symptoms as
measured with the BDI-13 or current psychosocial distress measured with
the GHQ-12 did not differ significantly between the groups.
Table 9. Characteristics of the controls, subjects with psychotic-like experiences and subjects with
manic-like experiences at 11–year follow-up








 n = 45
p
Gender (M/F) 30/32 32/54 20/25 .38b
Age 58.8 (9.8)1 57.2 (9.8)1 54.5 (9.1)1 .08a
BDI-13 3.2 (4.7)1 3.7 (3.7)1 3.9 (4.2)1 .71a
GHQ-12 2.0 (3.3)1 2.2 (3.2)1 2.1 (2.6)1 .95a
% % %
Good/nearly good
health status at 2011
66.1 67.4 53.3 .51b
Married/ cohabiting 79.0 76.8 66.7 .31b
Full/ part-time
employment
48.9 48.9 51.5 .66b




The prevalence of mental disorders at follow-up in each group is presented in
Table 10. The subjects with MLEs had the highest prevalence of psychiatric
disorders with a significant difference to the controls and the subjects with
PLEs.  Subjects  with  PLEs  and  controls  did  not  differ  in  prevalence  of
psychiatric disorders during follow-up. Comparisons were first calculated
only for a condition of any psychiatric disorder at follow-up due to small
numbers in specific diagnostic categories. However, in additional analysis,
there were no significant between-group differences in the amount of any
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depressive disorder during follow-up (with p values of p .85 for controls  vs.
PLEs, p .29 for controls vs. MLEs and p .34 for PLEs vs. MLEs). In these
analyses, subjects with comorbid depressive and anxiety disorder were
included.
There  was  only  one  subject,  with  baseline  MLEs,  who  developed  a
psychotic disorder during follow-up. There was no elevated amount of
dementia diagnoses in groups with PLEs or MLEs in the follow-up.
Table 10. Psychiatric diagnosis at 11-year follow-up in controls, subjects with psychotic-like
experiences and in subjects with manic-like experiences
Control























n % n % n % pa pa pa
Schizophrenia -   -   -   - 1 1.9
Bipolar disorder -   -   -    - - -
Depressive disorder 6 9.1   7   7.8 8 15.4





- -   2  2.2 1 1.9
Alcohol  use  -
related
disorder
2 3.0   3 3.3 3 5.8
Other psychiatric
disorder
- -   - 1 1.9
Any psychiatric
disorder1,2
9 13.6   14 15.5 16 30.8 .74 .02*     .03*
Dementia - - 1 1.1 - -
1 includes information from national registers as well as from interview and/or the Composite International Diagnostic
Interview at follow-up
2 diagnostic categories here include ICD-10 diagnoses for each diagnostic entity collected from the interview data. Register
information also covered diagnoses for suicide attempt and death by suicide but these were not found among the study subjects
a Chi2. *significant p < .05
In logistic regression analysis on baseline variables associating with later
psychiatric outcome with age, gender, PLEs or MLEs at baseline as
predictors,  MLEs  at  baseline  associated  with  an  increased  risk  for  a  future
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psychiatric condition (OR 2.78, CI 1.1-7.02, p .03). However, when lifetime
non-psychotic disorders at baseline were included in the model, previous
association was no longer significant, with only lifetime psychiatric illnesses
remaining highly significant predictors for future psychiatric disorders (OR
4.27, CI 1.94-9.36, p<.0001).
Cognitive performance at baseline was not significantly associated with
later psychiatric disorders in any of the groups.
66
5 DISCUSSION
The aim of the present thesis was to explore two middle-aged populations
who presumably had a higher risk for psychosis than the general population.
From schizophrenia family participants, cognitive performance of siblings
without current non-psychotic or psychotic psychiatric disorders was
compared to that of population controls. Levels of social and physical
anhedonia were studied in groups of siblings with and without non-psychotic
disorders, patients with schizophrenia spectrum disorders and population
controls. Associations of social and physical anhedonia with cognitive
performance were also explored. From a general population survey, groups
of participants with psychotic- or manic-like experiences, but with no
diagnosable psychotic disorder, were formed. Cognitive performance and
psychosocial functioning in these groups were compared to that of
population controls. Additionally, the predictive value of psychotic- or
manic-like experiences reported at baseline for psychiatric disorders at 11-
year follow-up was explored.
5.1 Cognitive performance of affected subjects, healthy
siblings and population controls (Study I)
In Study I, the main focus was to compare cognitive performance of healthy
siblings of schizophrenia patients to that of representative population-based
controls. The main finding was that healthy siblings had deficits in tasks that
required performance speed and in tasks with an executive component. The
siblings scored poorer than population controls both in the TMT A, requiring
simple visual-motor and attention, and in the TMT B, which also requires
set-shifting, divided attention and visual working memory. The results were
in  line  with  a  meta-analysis  on  methodologically  well-organized  studies  on
relatives of schizophrenia patients (Snitz et al. 2006), in which medium effect
sizes were found for performance differences in TMT A and B between
relatives and controls.
    Since the aforementioned tasks, used in Study I, had a performance
speed component, it might be that these differences relate mostly to the
slight slowness of performance of siblings in general. However, the difference
between groups remained after the speed component was subtracted,
suggesting that performance speed alone does not explain the difference and
an executive component may also be involved. Subtle executive dysfunction
in  siblings  of  schizophrenia  patients  (milder  than  found  in  patients  with
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schizophrenia) has also been observed in previous meta-analyses (Snitz et al.
2006;  Sitskoorn  et  al.  2004;  Szoke  et  al.  2005).  The  TMT  tasks  have  been
found to associate with frontally mediated cognitive operations (Stuss et al.
2001), but it should be noted that since these tasks require coordination of a
broad spectrum of cognitive abilities they are sensitive to brain dysfunction
with different aetiologies, as well as to brain dysfunction with several areas of
the brain (Andrewes, 2016).
Healthy siblings were slower in the Digit Symbol task than controls.
Coding tasks requiring processing speed have systematically been found to
be impaired in schizophrenia (Dickinson et al. 2007; Glahn et al. 2006). Digit
symbol is also a task requiring several performance components and can be
compromised regardless of the location of lesion (Lezak et al. 2004). Since
coding tasks require rapid and smooth coordination of a complex assembly of
elementary operations, poor performance in these tasks may implicate
deficient coordination, or failures of effective connectivity among distributed
brain networks, more than specific subprocesses (Dickinson et al. 2007).
Measures  for  performance  speed  and  executive  function  used  in  Study  I
also have a visual-spatial component (visual scanning and searching for a
target).  In  general,  spatial  tasks  are  complex  and  require  a  multitude  of
functions  which  means  that  deficits  in  those  tasks  may  relate  to  several
possible subprocesses (Andrewes, 2016). However, in a twin study of healthy
and schizophrenic co-twins using a spatial delayed response task, the
encoding or maintenance of spatial information was found to be the main
deficit (Glahn et al. 2003). Considering this, it may be that spatial processing
deficits contributed in part to the performance of siblings in TMT tasks and
Digit Symbol task.
Verbal learning and memory measures did not differ statistically
significantly between healthy siblings and population controls, although
there were findings indicative of less efficient use of semantic categories and
more recall errors in the CVLT in the siblings’ group. Also previously,
memory  deficits  in  relatives  of  patients  with  schizophrenia  have  been  mild
and not always statistically significant (Cirillo and Seidman, 2003; Conklin et
al. 2005). Most likely differences among studies also relate to the sensitivity
of the methods used. The CVLT used in Study I has been found to be a less
sensitive measure for verbal learning than some other methods, such as story
recall (e.g. the Logical Memory task of the WMS-R) or other list learning
tasks (e.g. Rey Auditory Verbal Learning Test) (Trandafir et al. 2006). This
has been attributed to the relative ease with which presented words can be
clustered based on their semantic features in the CVLT (Stone et al. 2011).
Verbal working memory as measured with digit span tasks did not differ
significantly between healthy siblings and population controls. Previously,
mild verbal working memory deficits have been found in healthy relatives of
schizophrenia patients (Snitz et al. 2006; Trandafir et al. 2006), and the
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deficits were found to scale in severity with genetic loading for schizophrenia
(Tuulio-Henriksson et al. 2002). It has been suggested that relatives perform
more poorly in working memory tasks with more executive demands
(Conklin et al. 2005). The digit span tasks used in the current study are
considered to be rather easy when compared with, for example, letter-
number sequencing or n-back tasks (Horan et al. 2008b; Lezak et al. 2012).
Neither general ability impairment nor severe memory dysfunction were
found in siblings.
Schizophrenia patients were impaired in all areas of cognitive functioning
compared with population controls and their healthy siblings. Findings are in
line with previous studies on generalized cognitive impairment in
schizophrenia (Heinrichs and Zakzanis, 1998; McIntosh et al. 2005; Franke
et al. 2016).
5.2 Associations of anhedonia and cognition (Study II)
The aim of Study II was to compare levels of social and physical anhedonia
among unaffected siblings and subjects with schizophrenia spectrum
disorders and with a population-based control group, and to further explore
associations of physical and social anhedonia with cognitive performance. In
comparisons  of  levels  of  social  and  physical  anhedonia,  measured  with  the
Chapman scales, the group of unaffected siblings was divided into those with
and those without non-psychotic psychiatric disorders. Interestingly, there
were no differences in the levels of physical or social anhedonia between
groups of siblings with and without non-psychotic psychiatric disorders and
population  controls.  Even  though  the  study  groups  were  small,  this  may
suggest that, regardless of familial liability to schizophrenia or the presence
of a non-psychotic psychiatric disorder, the siblings of affected persons do
not necessarily have elevated anhedonia.
    Elevated anhedonia in relatives of schizophrenia patients has previously
been found in some (Kendler et al. 1996; Laurent et al. 2000), but not all
studies  (Craver  and  Pogue-Geile,  1999;  Erlenmeyer-Kimling  et  al.  1993b).
Inconsistent findings may at least partly relate to methodological differences
as well as differences in study samples (Schürhoff et al. 2003). At biological
level, deficits in subcortical dopamine signalling have been found to
contribute to negative symptom severity and self-reported anhedonia
independent of diagnostic status in healthy controls, siblings of
schizophrenia patients and patients themselves (Eisenstein et al. 2017).
Specifically, higher striatal D2-receptor binding was associated with less
physical and social anhedonia across study groups (Eisenstein et al. 2017).
Subjects with schizophrenia spectrum disorder had significantly higher
levels of both social and physical anhedonia than either their unaffected
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siblings or population controls. Anhedonia is one of the negative symptoms
of schizophrenia and has repeatedly been shown to be elevated in subjects
with  schizophrenia  (Herbener  et  al.  2005;  Horan  et  al.  2007).  However,
studies using different methodology for measuring anhedonia have yielded
different results. While patients with schizophrenia reported more anhedonia
in relation to anticipatory items (Gard et al. 2007), they have been found to
report  normal  levels  of  pleasant  emotions  in  laboratory  studies  focusing  on
state emotions (Cohen and Minor, 2010).
In analyses on associations of physical and social anhedonia with cognitive
performance of the whole study population, elevated physical anhedonia was
associated with verbal memory deficits and with lower verbal ability. There
was no interaction of physical anhedonia and group status (schizophrenia
spectrum disorder, non-psychotic sibling or control) indicating that the effect
of physical anhedonia was similar in the general population subjects and
subjects with a familial vulnerability to psychosis. There is a possibility that
associations between physical anhedonia and verbal memory and verbal
ability could at least partly be explained by the demands of the assessment
method used (the Chapman Scales). Judgements concerning remembered or
anticipated events and the pleasure associated with them require the subject
to invoke an internal representation of the experience described in the
questionnaire and make a judgement about the affective value of said
representation  (Gold  et  al.  2008).  Being  able  to  make  those  judgements
requires cognitive processes including memory, insight, generalization and
prediction that are often compromised in schizophrenia (Horan et al. 2006a;
Rector et al. 2005) .
Social anhedonia did not associate statistically significantly with any of the
cognitive variables measured. However, there were two associations
suggestive of significance with verbal ability and verbal learning. Since there
was no interaction between group status and social anhedonia it would seem
that, as with physical anhedonia, the effect of social anhedonia on cognition
was  similar  in  all  study  groups.  In  the  model  including  both  physical  and
social anhedonia, only the effects of physical anhedonia on cognition
remained significant, suggesting that elevated physical anhedonia may be
more strongly related to cognition than social anhedonia. It should be noted
though, that in Study II there were no measures of social cognition in our test
battery. Previously, higher anhedonia has been found to correlate with worse
performance on a measure of emotion perception which has an important
role in social cognition (Herbener et al. 2008). Since impairment in social
interaction is a common symptom in schizophrenia spectrum disorders
(Velthorst et al. 2012), future studies addressing the relation of social
anhedonia and impaired processing of emotional stimuli in subjects with
vulnerability to schizophrenia are needed.
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Anhedonia is considered to be one of the main features in negative
symptom  dimensions  of  schizophrenia  (Wolf,  2006)  as  well  as  of  negative
schizotypy, which is considered to be a latent liability to schizophrenia on the
level of personality with positive and negative schizophrenia-resembling
symptoms  (Lahti  et  al.  2009).  Negative  symptoms  have  been  found  to
associate with a variety of cognitive domains in patients with schizophrenia
(Lincoln et al. 2016; Szendi et al. 2006; Winograd-Gurvich et al. 2006). The
relationship of cognitive deficits and negative schizotypal traits in subjects
who have a genetic risk for developing schizophrenia is more complex
(Delawalla et al. 2006). Our results in Study II suggest that elevated physical
anhedonia relates to poorer performance in some of the verbal measures but
separately from the effect of familial liability. In a meta-analysis by Snitz et
al. (2006), schizotypal personality disorder or schizotypal symptoms did not
have an effect on cognitive functioning of non-affected first-degree relatives
of schizophrenia patients. A clinical high-risk study on adolescents suggested
that the effects of genetic risk and clinical status on cognitive functioning are
independent, and that cognitive impairment can occur in genetically
vulnerable individuals regardless of their clinical status (Myles-Worsley et al.
2007).
However, social and physical anhedonia are only one dimension of
negative symptoms. Since there are several different scales that are used to
measure  negative  symptoms to  begin  with  (Lincoln  et  al.  2017),  our  results
should be interpreted within the context of self-reported ability, or the lack of
it, in  experienced physical and social anhedonia as measured with the
Chapman scales. With new information on neural bases of experiences of
emotion,  it  has  been  suggested  that  in  the  future  studies  on  affective
symptoms of schizophrenia need to be done with systematic methodology
and  be  multidisciplinary,  with  enough  emphasis  on  neural  and  cognitive
processes behind reported experience of emotions (Cohen et al. 2011; Dollfus
and Lyne, 2016).
5.3 Psychosocial and cognitive characteristics of subjects
with psychotic-like or manic-like experiences (Study III)
Study III aimed at comparing cognitive performance and psychosocial
functioning in subjects with psychotic-like or manic-like experiences (PLEs
or MLEs) and controls from a general population survey sample of adults
aged 30–70 years. No major differences in cognitive performance were
found. Subjects with MLEs had slightly worse psychosocial functioning and
more depressive symptoms than controls, although differences were small.
They had also had more lifetime non-psychotic psychiatric disorders and
more psychiatric comorbidity than controls. MLEs were also related to
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interpersonal functioning, as subjects in this group were more often living
alone than controls or subjects with PLEs. Altogether, these findings suggest
more pronounced difficulties in daily life and also possibly in interpersonal
relationships  for  people  with  MLEs  than  in  the  other  groups,  even  though
occupational functioning was at the same level as controls.
    In patients with bipolar disorder, cognitive and emotional
abnormalities, as well as impairment in subjective (i.e. perceived quality of
life) and objective (i.e. occupational, physical and interpersonal) functioning,
are often present (Martinez-Aran et al. 2007). It has been shown that
cognitive deficits in these patients predict psychosocial outcome
independently of mood symptoms (Van Rheenen and Rossell, 2014).
Therefore, it is of interest that in Study III the subjects with MLEs who had a
comparable cognitive ability to that of controls still had several similarities,
albeit in a rather mild form, to bipolar patients in psychosocial and mood
measures. This may suggest that when MLEs are present, they may have an
influence on a person’s life despite average occupational and cognitive
functioning.
However, it has been suggested that mean age of onset for bipolar disorder
may fall into three categories: having peaks in twenties, thirties and also
forties with 55 % of patients in middle or late onset groups (Hamshere et al.
2009;  Bauer  et  al.  2014).  Hence,  it  is  possible  that  there  may  have  been
subjects in our group with MLEs who are still at risk for later conversion to a
bipolar disorder or another psychiatric condition.
   The only significant difference between subjects with PLEs and controls
was slightly worse psychosocial functioning. Interestingly, no differences in
the amount of non-psychotic psychiatric disorders were found in subjects
with PLEs and controls. The prevalence of PLEs has been found to be more
than twice higher in individuals with depressive and anxiety disorders than
in people without these disorders (Wigman et al. 2012). The results suggest
that when studying subjects from the general population without a clinical
framework, the presence of non-psychotic psychiatric conditions may be
similar in subjects with and without PLEs. The results also differ from those
found  in  the  Adult  Psychiatric  Morbidity  Survey  (Freeman  et  al.  2011),  but
since we excluded subjects with a current psychiatric disorder our results are
informative  of  the  significance  of  PLEs  when they  are  not  part  of  a  current
psychiatric symptomatology.
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5.4 Associations of psychotic-like and manic-like
experiences with later psychiatric disorders (Study IV)
The aim of Study IV was to study whether PLEs, MLEs or neuropsychological
performance at baseline associated with psychiatric disorders after an 11-year
follow-up period. The main finding was that neither PLEs nor MLEs
measured at the Health 2000 baseline assessment predicted conversion to
psychosis during an eleven-year follow-up. In general, developing a psychosis
during  a  follow-up  is  very  rare.  There  was  only  one  conversion  to
schizophrenia  concerning  a  subject  with  baseline  MLEs.  During  the  follow-
up, subjects with MLEs had significantly more non-psychotic psychiatric
disorders as well as hospital treatment for these disorders than either
controls or subjects with PLEs. However, further analyses showed that this
was explained by having more lifetime psychiatric disorders already at the
baseline assessment.
    Since hypomanic personality has previously been found to predict
psychiatric disorders in young adult samples (Kwapil et al. 2000; Miettunen
et al. 2011), it is of interest that baseline MLEs did not predict bipolar
disorder or other severe mental disorders in this study. However, the sample
size of the study groups was relatively small considering the incidence rates
of psychotic disorders, particularly in the age group of the present study.
Thus, it is possible that with larger study samples the results could have been
different.
 There have been studies about the relationship between bipolar disorder
and borderline personality disorder (Antoniadis et al. 2012), and it has been
found that there is some overlap in self-reported symptoms of bipolar
disorder  and  borderline  personality  disorder,  as  well  as  some  overlap  in
phenomenological and neurobiological features of these disorders
(Baryshnikov et al. 2015). Whether MLEs reported in the CIDI reflect bipolar
disorder susceptibility or more broadly unspecific affective instability
without pronounced psychotic susceptibility remains open. Even though the
subjects with MLEs did not have a diagnosis of bipolar disorder or borderline
personality disorder at baseline, it may be that some of them share similar
subthreshold features or vulnerability, possibly predisposing them to some
future psychiatric condition or having a relapse to the same condition as
before. Previously it has been found that subthreshold affective symptoms
and substance use disorders in young subjects might predict bipolar disorder
(Ratheesh et al. 2015b). However, studies are few and no established tools to
identify individuals at risk for developing bipolar disorder have yet been
developed (Bechdolf et al. 2014).
The subject with PLEs did not differ from the controls in the prevalence of
psychiatric  disorders  during  follow-up.  None  of  the  subjects  with  PLEs  had
psychosis during the follow-up, suggesting that PLEs in middle-aged subjects
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may not predict future psychosis. Even though psychotic experiences mostly
have  onset  in  adolescence  or  young  adulthood,  there  are  subjects  with  late
onset psychotic experiences (McGrath et al. 2016). Werbeloff et al. (2012)
followed  a  cohort  of  young  subjects  for  24  years  and  found  that  PLEs
predicted a risk for later hospitalization for non-affective psychosis, but
mostly during the first five years after baseline. Because their study subjects
were relatively young (mean age at baseline 29.4), the possibility of a lengthy
prodromal period could not be ruled out. Still, their study found a transition
rate at around 1% during the first 5 years (Werbeloff et al. 2012). In our
study,  the  subjects  were  significantly  older  at  baseline,  with  a  mean  age  of
49.5 years in the PLE group, 46.8 years in the MLE group and 50.6 years in
the  control  group,  so  most  likely  there  were  no  subjects  with  prodromal
symptoms. In a study by Werbeloff and colleagues (2012), the cumulative
incidence of later psychotic hospitalization associated with attenuated
psychotic symptoms was higher in respondents with poor social functioning
at baseline. Moreover, impaired social functioning has been found to be a
risk factor for future schizophrenia (Krabbendam et al. 2004). The subjects
with PLEs reported slightly poorer current psychosocial functioning levels
than  controls  at  baseline  (assessed  with  the  GAF),  but  they  might  not  have
been as severe as with subjects who later developed psychosis (Sparks et al.
2010).
Neuropsychological performance at baseline did not associate with later
psychiatric disorders in subjects with PLEs or MLEs. Neuropsychological
deficits  have  previously  been  found to  predict  psychosis  in  adolescents  and
young adults in Clinical High Risk (CHR) samples (Keefe et al, 2006; Wood
et  al,  2007)  as  well  as  in  subjects  with  a  family  history  of  schizophrenia
(Erlenmeyer-Kimling et al, 2000). Keefe et al. (2006) found that those CHR
subjects who progressed to psychosis had more severe deficits, while other
at-risk subjects did not differ significantly from controls in
neuropsychological performance. In studies on the associations of cognitive
functions  and  future  bipolar  disorder,  lower  visuospatial  functions  and
higher arithmetic functions at age 20 have been found to associate with
greater odds for later bipolar disorder in male conscripts (Tiihonen et al.
2005). In other studies, young subjects who later developed bipolar disorder
have been found not to differ from controls (Reichenberg et al. 2002;
Reichenberg et al. 2002; Zammit et al. 2004) or even have above average
cognitive functioning (MacCabe et al. 2013).
Better performance in some of the verbal memory measures at baseline
was associated with lower likelihood for later psychiatric disorders in the
controls. Previously, better performance in verbal memory measures has
been associated with lower likelihood of later psychiatric disorder in general
population studies (Gale et al. 2011) and in cohort studies (Martin et al.
2007).
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In conclusion, the results suggest that MLEs and PLEs are not effective
predictors of severe psychiatric disorders beyond young adulthood. However,
future studies with larger study groups are warranted.
5.5 Methodological considerations
All  participants  of  the  present  thesis  were  drawn  from  the  Finnish
population, and they were assessed applying systematic methodological and
diagnostic procedures. Healthy siblings of the schizophrenia patients,
subjects with PLEs and MLEs and the control subjects included in the studies
were without current mental or substance use disorders, diminishing the
potentially confounding effect of other conditions on neuropsychological
assessment. The neuropsychological assessment and psychiatric evaluation
were done in a systematic manner for all subjects. In addition, control
subjects in the study were a representative sample from the Finnish
population. Because psychiatric symptoms and mild psychiatric disorders are
relatively  common  in  the  general  population,  the  controls  with  a  lifetime,
non-psychotic Axis I disorders were included, while those with a current
disorder  were  excluded.   This  was  done  in  order  to  avoid  selection  of  an
atypical, “super-normal”, control sample.
   Statistical methods used for Studies I and II including family data were
adjusted for family correlation. The modifying effects of demographic
variables such as age, gender and education were controlled for in all of the
analyses. Moreover, most subjects in the schizophrenia family data were over
the mean risk age for conversion to schizophrenia, which is below 40 years of
age (Franke et al. 1994). This made it less likely that the non-psychotic
disorders  in  the  sibling  group  would  turn  into  psychosis  or  that  the
neuropsychological deficits found would have been related to the prodromal
period preceding psychosis. The PLE and MLE subjects in Studies III and IV
were also middle-aged, making it possible to study potential risk symptoms
for psychotic disorders in an age group scarcely previously studied.
There are several methodological limitations. Studies I and II represent
neuropsychological functioning in familial schizophrenia. Thus, our results
may not be generalizable, as such, to all situations. The neuropsychological
test battery that was used in all of the Studies could have been more
thorough with the inclusion of measures for social cognition, visual reasoning
and visual  memory.  Also,  it  is  possible that  if  more demanding measures of
memory, attention and executive functioning had been used it could have
revealed more differences between groups. The CVLT, which has been widely
used in research on cognition in psychotic disorders, was also used as a
measure of verbal learning and memory in this study. Although its use allows
comparison with international studies, the test has not been validated in
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Finnish. This can be considered as a limitation to the present study. In Study
II, a more effective or up-to-date assessment method of anhedonia, other
than the Chapman scales, with a method for differentiating consummatory
and anticipatory or remembered pleasure, might have yielded additional
information on the relationship between neuropsychological performance
and anhedonia. In Studies III and IV the decision not to use Bonferroni
correction was made because diminishing power in already low power
analyses (small sample sizes) might have increased the risk of not detecting a
true difference. The Bonferroni correction has been criticized for causing loss
of power to detect real effects (Glickman, 2014), which influenced the
decision not to perform Bonferroni adjustment. Considering the relatively
small sample sizes in all of the present studies, generalizability may be
limited, and further research is needed to confirm these findings.
    In  Studies  III  and  IV,  the  focus  was  on  subjects  with  PLEs  or  MLEs,
derived from the CIDI, who also went through a thorough diagnostic
procedure  of  the  Psychosis  in  Finland  of  the  Health  2000  Study  with  no
observed diagnoses for a psychotic disorder. Because PLEs and MLEs are
defined as subthreshold symptoms, and the CIDI is designed as a diagnostic
tool  for  mental  disorders,  it  can be argued that our subjects  with PLEs and
MLEs do have relatively noticeable subthreshold psychotic experiences.
However, the CIDI has been criticized for not being sensitive enough, being
able  to  detect  only  26.6%  of  subjects  with  a  psychotic  disorder  and  25%  of
those with bipolar disorder (Perälä et al. 2007). Therefore, even though the
CIDI  may  be  considered  to  have  been  rather  strict  on  one  hand,  one  might
question whether more subjects with PLEs or MLEs could have been found
with a different methodology. Adding another measure for PLEs and MLEs
would have made comparison of methodology possible and added reliability.
5.6 General discussion and conclusions
Different aspects of the relationship between cognitive performance and
susceptibility to psychosis were explored in Studies I-IV where the focus was
on less-studied middle-aged subjects, instead of adolescents/young adults
who  have  been  studied  more  often.  According  to  the  results  of  the  study,
healthy siblings of schizophrenia patients seemed to have mild but
recognizable deficits in neuropsychological performance in comparison to
population controls, even when the siblings with non-psychotic disorders are
excluded (Study I). Elevated physical anhedonia related to poorer
performance on some measures of verbal function, but the effect was
separate  from  the  effect  of  familial  liability  on  cognition  (Study  II).  The
detected cognitive deficits were mild and most likely to not severely interfere
with daily life, considering that people in general have marked heterogeneity
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in their cognitive profile and performance. However, considering that the
education level of the siblings was closer to that of affected subjects than to
that of controls, it is possible that these deficits, although mild, might have
affected the achieved education level or educational demands of professions
selected within this group. Unfortunately, these aspects were not explored
further and should be studied in future.
Middle-aged subjects with psychotic-like or manic-like experiences,
assessed with relatively strict criteria, did not differ significantly from control
subjects regarding cognitive functioning. Most interestingly, the subjects
with PLEs were more similar to controls in psychosocial and occupational
functioning than subjects with MLEs (Study III). Subjects with MLEs had
more lifetime psychiatric disorders and also differed from controls in
interpersonal, but not occupational, functioning, suggesting that despite a
good enough performance in professional life there may be some form of
psychological fragility present in these subjects. In this age group, neither
PLEs nor MLEs predicted future psychosis in an 11-year follow-up (Study
IV), suggesting that in middle-aged persons these symptoms may be more
benign regarding risk for conversion to psychosis than in younger people. In
the future, investigating larger samples with PLEs and MLEs with a broader
methodological perspective, including personality assessment, would be
recommended.
5.7 Implications for clinical practice and future research
This thesis focused on adult subjects who presumably had a more
pronounced risk for psychotic disorders than a general population without
familial or clinical risk features. In general, these middle-aged subjects
seemed to differ from younger at-risk (whether clinical or familial) subjects.
   Relatives of schizophrenia patients have neuropsychological deficits that
are milder than those of affected subjects. In familial schizophrenia, these
neuropsychological deficits seem to be related partly to familial vulnerability
as well as to the shared genetic features among family members, even though
with  affected  subjects  the  deficits  are  more  severe.  In  clinical  practice,  it  is
important to notice that middle-aged, or older, mentally healthy relatives of
schizophrenia patients may have mild neuropsychological impairment, in
order to be able to interpret findings correctly when assessing cognitive
function of such persons for reasons such as a suspected neurological
condition.
In non-psychotic subjects from schizophrenia families, physical and social
anhedonia  levels  were  not  different  from those  of  population  controls.  This
may suggest that elevated anhedonia is more specifically related to the illness
itself than familial vulnerability, and therefore should in clinical settings be
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taken seriously. Studies that use different measures of anhedonia than self-
report scales may offer new insight into the phenomenon of negative
symptoms of schizophrenia.
PLEs are a part of clinical vulnerability to psychosis and, in CHR settings
(adolescents and young adults), are known to be associated with the
prodromal period that anticipates the onset of psychosis. In CHR settings
they also associate with neuropsychological deficits. PLEs are relatively
common in the general population with prevalence of about 7% (Linscott and
van Os, 2013). In middle-aged subjects from a general population survey, the
subjects with PLEs did not differ from population controls in any assessed
cognitive function, nor in incidental non-psychotic psychiatric disorders.
PLEs or MLEs did not predict conversion to psychosis during 11-year follow-
up in middle-aged adults.
It may be that in non-help-seeking middle-aged subjects these experiences
are of a benign nature. Since cognitive functioning of subjects with PLEs did
not  differ  from  that  of  controls,  it  may  also  be  that  sufficient  cognitive
functioning might have protected against full manifestation of psychosis. In
general, the study suggests that in middle-aged subjects who have no history
of a psychotic disorder, the presence of PLEs does not seem to represent
susceptibility to psychosis, nor to non-psychotic psychiatric disorders. This
does not imply, however, that disturbing PLEs should not be taken seriously
in clinical practice.
Even though manic-like experiences did not predict a psychotic disorder
during  the  11-year  follow-up,  it  should  be  noted  that  in  comparison  to
controls and subjects with PLEs the subjects with MLEs had several distress-
related findings at baseline and more non-psychotic psychiatric disorders,
deaths and dropouts during follow-up than other subjects (also those with
PLEs).   Clinically, MLEs or other symptoms suggestive of affective instability
should be taken seriously and possible supportive or treatment options
should be carefully considered. If a patient manifests PLEs or MLEs as well
as compromised neuropsychological performance, thorough clinical
evaluation of the situation is warranted.
    In  future  research,  a  long-term  follow-up  period  would  add  to  our
knowledge  of  susceptibility  to  psychosis  and  other  mental  disorders  in
middle-aged populations with different vulnerability features. Of particular
interest  would  be  to  study  the  aging  process  of  the  siblings’  group  with
reassessment of neuropsychological and psychiatric measures. A possible
predictive value of neuropsychological impairment at baseline in this
population might manifest itself.
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